

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

RELATED APPLICATIONS

This application claims priority from USSN 60/256,635 filed December 18, 2000 (Cura-524); USSN 60/259,743 filed January 4, 2001 (Cura-524 A); USSN 60/299,327 filed
5 June 19, 2001 (Cura-524 A1); USSN 60/261,498 filed January 12, 2001 (Cura-524 B); USSN 60/263,689 filed January 24, 2001 (Cura-524 C); USSN 60/267,464 filed February 8, 2001 (Cura-524 D); USSN 60/271,021 filed February 22, 2001 (Cura-524 E); USSN 60/275,946 filed March 14, 2001 (Cura-524 F); USSN 60/278,150 filed March 23, 2001 (Cura 524 G); USSN 60/285,718 filed April 23, 2001 (Cura-524 H); USSN 60/312,902 filed August 16,
10 2001 (Cura-524 I); 60/257,876 filed December 21, 2000 (Cura-527); USSN 60/260,718 filed January 10, 2001 (Cura-527 A); and USSN 60/284,591 filed April 18, 2001 (Cura-527 B), each of which is incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

The invention generally relates to nucleic acids and polypeptides. More particularly,
15 the invention relates to nucleic acids encoding novel G-protein coupled receptor (GPCR) polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding
20 novel polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "GPCRX" nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated GPCR_X nucleic acid molecule encoding a GPCR_X polypeptide that includes a nucleic acid sequence that has identity to the
25 nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127. In some embodiments, the GPCR_X nucleic acid molecule will hybridize under

stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a GPCR_X nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a GPCR_X polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least
5 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid
10 sequence of any of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127. Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a GPCR_X nucleic acid (*e.g.*, SEQ ID NOS: 1, 3,
15 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127) or a complement of said oligonucleotide.

Also included in the invention are substantially purified GPCR_X polypeptides (*e.g.*,
20 SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128). In certain embodiments, the GPCR_X polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human GPCR_X polypeptide.

25 The invention also features antibodies that immunoselectively bind to GPCR_X polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a GPCR_X nucleic acid, a
30 GPCR_X polypeptide, or an antibody specific for a GPCR_X polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a GPCR_X nucleic acid, under conditions allowing for expression of the GPCR_X polypeptide encoded by the DNA. If desired, the GPCR_X polypeptide can then be recovered.

5 In another aspect, the invention includes a method of detecting the presence of a GPCR_X polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the GPCR_X polypeptide within the sample.

10 The invention also includes methods to identify specific cell or tissue types based on their expression of a GPCR_X.

Also included in the invention is a method of detecting the presence of a GPCR_X nucleic acid molecule in a sample by contacting the sample with a GPCR_X nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a GPCR_X nucleic acid molecule in the sample.

15 In a further aspect, the invention provides a method for modulating the activity of a GPCR_X polypeptide by contacting a cell sample that includes the GPCR_X polypeptide with a compound that binds to the GPCR_X polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, developmental diseases; MHCII and III diseases (immune diseases); taste and scent
25 detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances;
30 potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM1); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-

associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; Dentatorubro-pallidoluysian atrophy (DRPLA); Hypophosphatemic rickets; autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome; immune disorders; adrenoleukodystrophy; congenital adrenal hyperplasia; hemophilia; hypercoagulation; idiopathic thrombocytopenic purpura; autoimmune disease; immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; stroke; tuberous sclerosis; hypercalcaemia; cerebral palsy; epilepsy; Lesch-Nyhan syndrome; ataxia-telangiectasia; Leukodystrophies; Behavioral disorders; Addiction; Neuroprotection; cirrhosis; transplantation; systemic lupus erythematosus; emphysema; scleroderma; ARDS; renal artery stenosis; interstitial nephritis; glomerulonephritis; polycystic kidney disease; systemic lupus erythematosus; renal tubular acidosis; IgA nephropathy; cardiomyopathy; atherosclerosis; congenital heart defects; aortic stenosis ; atrial septal defect (ASD); atrioventricular (A-V) canal defect; ductus arteriosus; pulmonary stenosis ; subaortic stenosis; ventricular septal defect (VSD); valve diseases; scleroderma; fertility; pancreatitis; endocrine dysfunctions; growth and reproductive disorders; inflammatory bowel disease; diverticular disease; leukodystrophies; graft vesus host; hyperthyroidism; endometriosis; hematopoietic disorders and/or other pathologies and disorders of the like. The therapeutic can be, *e.g.*, a GPCR_X nucleic acid, a GPCR_X polypeptide, or a GPCR_X-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders listed above and/or other pathologies and disorders.

The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding GPCR_X may be useful in gene therapy, and GPCR_X may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for

treatment of patients suffering the diseases and disorders listed above and/or other pathologies and disorders.

The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, diseases and disorders listed above and/or other pathologies and disorders and those disorders related to cell signal processing and metabolic pathway modulation. The method includes contacting a test compound with a GPCR_X polypeptide and determining if the test compound binds to said GPCR_X polypeptide. Binding of the test compound to the GPCR_X polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to an disorders or syndromes including the diseases and disorders listed above and/or other pathologies and disorders or other disorders related to cell signal processing and metabolic pathway modulation by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a GPCR_X nucleic acid. Expression or activity of GPCR_X polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses GPCR_X polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of GPCR_X polypeptide in both the test animal and the control animal is compared. A change in the activity of GPCR_X polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a GPCR_X polypeptide, a GPCR_X nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the GPCR_X polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the GPCR_X polypeptide present in a control sample. An alteration in the level of the GPCR_X polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes diseases and disorders listed above and/or other pathologies and disorders. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a GPCR_X polypeptide, a GPCR_X nucleic acid, or a GPCR_X-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes the diseases and disorders listed above and/or other pathologies and disorders.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The invention is based, in part, upon the discovery of novel nucleic acid sequences that encode novel polypeptides. The nucleic acids, and their encoded polypeptides, are collectively designated herein as “GPCR_X”.

The novel GPCR_X nucleic acids of the invention include the nucleic acids whose sequences are provided in Table 1 (at the end of the Detailed Description), or a fragment, derivative, analog or homolog thereof. All of the sequences listed in the attached Table 1 have a high degree of homology to known GPCR sequences. Exemplary homology for the sequences is provided in the provisional applications from which the present application claims priority. This homology data are incorporated herein by reference in their entirety. Within the scope of this invention is a method of using these nucleic acids and peptides in the

treatment or prevention of a disorder related to cell signaling or metabolic pathway modulation.

G-Protein Coupled Receptor proteins ("GPCRs") have been identified as a large family of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of various signals. Human GPCR generally do not contain introns and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. See, e.g., Ben-Arie et al., *Hum. Mol. Genet.* 1994 3:229-235; and, Online Mendelian Inheritance in Man ("OMIM") entry#164342(<http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?>).

The olfactory receptor ("OR") gene family constitutes one of the largest GPCR multigene families and is distributed among many chromosomal sites in the human genome. See Rouquier et al., *Hum. Mol. Genet.* 7(9):1337-45 (1998); Malnic et al., *Cell* 96:713-23 (1999). Olfactory receptors constitute the largest family among G protein-coupled receptors, with up to 1000 members expected. See Vanderhaeghen et al., *Genomics* 39(3):239-46 (1997); Xie et al., *Mamm. Genome* 11(12):1070-78 (2000); Issel-Tarver et al., *Proc. Natl. Acad. Sci. USA* 93(20):10897-902 (1996). The recognition of odorants by olfactory receptors is the first stage in odor discrimination. See Krautwurst et al., *Cell* 95(7):917-26 (1998); Buck et al., *Cell* 65(1):175-87 (1991). Many ORs share some characteristic sequence motifs and have a central variable region corresponding to a putative ligand binding site. See Issel-Tarver et al., *Proc. Natl. Acad. Sci. USA* 93:10897-902 (1996).

Other examples of seven membrane spanning proteins that are related to GPCRs are chemoreceptors. See Thomas et al., *Gene* 178(1-2):1-5 (1996). Chemoreceptors have been identified in taste, olfactory, and male reproductive tissues. See *id.*; Walensky et al., *J. Biol. Chem.* 273(16):9378-87 (1998); Parmentier et al., *Nature* 355(6359):453-55 (1992); Asai et al., *Biochem. Biophys. Res. Commun.* 221(2):240-47 (1996).

The GPCRX nucleic acids of the invention encoding GPCR-like proteins include the nucleic acids whose sequences are provided herein, or fragments thereof. The invention also includes mutant or variant nucleic acids any of whose bases may be changed from the corresponding base shown herein while still encoding a protein that maintains its GPCR-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described,

including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

The GPCRX proteins of the invention include the GPCR-like proteins whose sequences are provided herein. The invention also includes mutant or variant proteins any of whose residues may be changed from the corresponding residue shown herein while still encoding a protein that maintains its GPCR-like activities and physiological functions, or a functional fragment thereof. The invention further encompasses antibodies and antibody fragments, such as F_{ab} or (F_{ab})₂, that bind immunospecifically to any of the proteins of the invention.

The GPCRX nucleic acids and proteins are useful in potential therapeutic applications implicated in various GPCR-related pathological disorders and/or OR-related pathological disorders, described further below. For example, a cDNA encoding the GPCR (or olfactory-receptor) like protein may be useful in gene therapy, and the receptor -like protein may be useful when administered to a subject in need thereof. The nucleic acids and proteins of the invention are also useful in potential therapeutic applications used in the treatment of developmental diseases; MHCII and III diseases (immune diseases); taste and scent detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances; potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM1); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright hereditary osteodystrophy; angina pectoris; myocardial infarction; ulcers;

allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; dentatorubro-pallidoluyisian atrophy (DRPLA); hypophosphatemic rickets; autosomal dominant (2) acrocallosal syndrome and

5 dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome; immune disorders; adrenoleukodystrophy; congenital adrenal hyperplasia; hemophilia; hypercoagulation; idiopathic thrombocytopenic purpura; autoimmune disease; immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; stroke; tuberous sclerosis; hypercalceimia; cerebral palsy; epilepsy; Lesch-Nyhan syndrome; ataxia-

10 telangiectasia; leukodystrophies; behavioral disorders; addiction; neuroprotection; cirrhosis; transplantation; systemic lupus erythematosus; emphysema; scleroderma; ARDS; renal artery stenosis; interstitial nephritis; glomerulonephritis; polycystic kidney disease; systemic lupus erythematosus; renal tubular acidosis; IgA nephropathy; cardiomyopathy; atherosclerosis; congenital heart defects; aortic stenosis ; atrial septal defect (ASD); atrioventricular (A-V)

15 canal defect; ductus arteriosus; pulmonary stenosis ; subaortic stenosis; ventricular septal defect (VSD); valve diseases; scleroderma; fertility; pancreatitis; endocrine dysfunctions; growth and reproductive disorders; inflammatory bowel disease; diverticular disease; leukodystrophies; graft vesus host; hyperthyroidism; endometriosis; hematopoietic disorders and/or other pathologies and disorders. Other GPCR-related diseases and disorders are

20 contemplated.

The protein similarity information, expression pattern, and map location for the olfactory receptor-like GPCR proteins and nucleic acids disclosed herein suggest that these olfactory receptors may have important structural and/or physiological functions characteristic of the olfactory receptor family. Therefore, the GPCR nucleic acids and

25 proteins are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic,

30 drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

GPCR polypeptides are useful in the generation of antibodies that bind immunospecifically to the GPCR polypeptides of the invention, and as vaccines. The antibodies are for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the “Anti-GPCR_X Antibodies” section below.

GPCR polypeptides can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders. The novel nucleic acid encoding GPCR-like protein, and the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

GPCR_X Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode GPCR_X polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify GPCR_X-encoding nucleic acids (*e.g.*, GPCR_X mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of GPCR_X nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

A GPCR_X nucleic acid can encode a mature GPCR_X polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more

naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated GPCR α nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or

culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 as a hybridization probe, GPCR_X molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to GPCR_X nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109,

111, 113, 115, 117, 119, 121, 123, 125 and 127, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a GPCR_X polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, thereby forming a stable duplex.

As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case

of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See *e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of GPCR_X polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a GPCR_X polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous

nucleotide sequence does not, however, include the exact nucleotide sequence encoding huma GPCR_X protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, as well as a polypeptide possessing GPCR_X biological activity. Various biological activities of the GPCR_X proteins are described below.

A GPCR_X polypeptide is encoded by the open reading frame ("ORF") of a GPCR_X nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the huma GPCR_X genes allows for the generation of probes and primers designed for use in identifying and/or cloning GPCR_X homologues in other cell types, e.g. from other tissues, as well as GPCR_X homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71,

73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127.

Probes based on the huma GPCR_X nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various
5 embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a GPCR_X protein, such as by measuring a level of a GPCR_X-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting GPCR_X mRNA levels or determining
10 whether a genomic GPCR_X gene has been mutated or deleted.

“A polypeptide having a biologically-active portion of a GPCR_X polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-
15 active portion of GPCR_X" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 that encodes a polypeptide having a GPCR_X biological activity (the biological activities of the GPCR_X proteins are described
20 below), expressing the encoded portion of GPCR_X protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of GPCR_X.

GPCR_X Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29,
25 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 due to degeneracy of the genetic code and thus encode the same GPCR_X proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61,
30 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having

an amino acid sequence shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. In addition to the huma GPCR_X nucleotide sequences shown in
5 SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the GPCR_X polypeptides may exist within a
10 population (*e.g.*, the human population). Such genetic polymorphism in the GPCR_X genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a GPCR_X protein, preferably a vertebrate GPCR_X protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide
15 sequence of the GPCR_X genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the GPCR_X polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the GPCR_X polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding GPCR_X proteins from other species, and
20 thus that have a nucleotide sequence that differs from the human sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and
25 homologues of the GPCR_X cDNAs of the invention can be isolated based on their homology to the huma GPCR_X nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the
30 invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107,

109, 111, 113, 115, 117, 119, 121, 123, 125 and 127. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent
5 conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding GPCR_X proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or
10 high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in
15 different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target
20 sequence at equilibrium. Since the target sequences are generally present at excess, at T_m, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for
25 longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%,
30 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm

DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. See, *e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). See, *e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A

Conservative Mutations

5 In addition to naturally-occurring allelic variants of GPCR_X sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 10 117, 119, 121, 123, 125 and 127 thereby leading to changes in the amino acid sequences of the encoded GPCR_X proteins, without altering the functional ability of said GPCR_X proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 15 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the GPCR_X proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the 20 GPCR_X proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding GPCR_X proteins that contain changes in amino acid residues that are not essential for activity. Such GPCR_X proteins differ in amino acid sequence from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 25 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% 30 homologous to the amino acid sequences of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. Preferably, the protein encoded by the nucleic acid

molecule is at least about 60% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128; more preferably at least about 70% homologous to

5 SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128; still more preferably at least about 80% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128; even more preferably at least about 90% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128; and most preferably at least about 95% homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. An isolated nucleic acid molecule encoding a GPCR_X protein homologous to the protein of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid

substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the GPCR_X protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a GPCR_X coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for GPCR_X biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant GPCR_X protein can be assayed for (i) the ability to form protein:protein interactions with other GPCR_X proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant GPCR_X protein and a GPCR_X ligand; or (iii) the ability of a mutant GPCR_X protein to bind to an intracellular target protein or biologically-active portion thereof; (*e.g.* avidin proteins).

In yet another embodiment, a mutant GPCR_X protein can be assayed for the ability to regulate a specific biological function (*e.g.*, regulation of insulin release).

Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (*e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire GPCR_X coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a GPCR_X protein of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, or antisense nucleic acids complementary to a GPCR_X nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a GPCR_X protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the GPCR_X protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the GPCR_X protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of GPCR_X mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of GPCR_X mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of GPCR_X mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or

genomic DNA encoding a GPCR α protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.

Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. See, *e.g.*, Gaultier, *et al.*, 1987. *Nucl. Acids Res.* **15**: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (see, *e.g.*, Inoue, *et al.* 1987. *Nucl. Acids Res.* **15**: 6131-6148) or a chimeric RNA-DNA analogue (see, *e.g.*, Inoue, *et al.*, 1987. *FEBS Lett.* **215**: 327-330).

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave

GPCRX mRNA transcripts to thereby inhibit translation of GPCR_X mRNA. A ribozyme having specificity for a GPCR_X-encoding nucleic acid can be designed based upon the nucleotide sequence of a GPCR_X cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a GPCR_X-encoding mRNA. See, *e.g.*, U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* GPCR_X mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, GPCR_X gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the GPCR_X nucleic acid (*e.g.*, the GPCR_X promoter and/or enhancers) to form triple helical structures that prevent transcription of the GPCR_X gene in target cells. See, *e.g.*, Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the GPCR_X nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, *e.g.*, Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g.*, DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of GPCR_X can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of GPCR_X can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.*, PNA directed PCR clamping; as artificial restriction enzymes

when used in combination with other enzymes, *e.g.*, S₁ nucleases (*see*, Hyrup, *et al.*, 1996.*supra*); or as probes or primers for DNA sequence and hybridization (*see*, Hyrup, *et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of GPCR_X can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of GPCR_X can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.*, RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (*see*, Hyrup, *et al.*, 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g.*, Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g.*, Finn, *et al.*, 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. *See, e.g.*, Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g.*, Krol, *et al.*, 1988. *BioTechniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

GPCRX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of GPCR_X polypeptides whose sequences are provided in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128 while still encoding a protein that maintains its GPCR_X activities and physiological functions, or a functional fragment thereof.

In general, a GPCR_X variant that preserves GPCR_X-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated GPCR_X proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-GPCR_X antibodies. In one embodiment, native GPCR_X proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, GPCR_X proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a GPCR_X protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the GPCR_X protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of GPCR_X proteins in which the protein is separated from cellular components of the cells from which it is isolated or

recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of GPCR_X proteins having less than about 30% (by dry weight) of non-GPCR_X proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-GPCR_X proteins, still more preferably less than about 10% of non-GPCR_X proteins, and most preferably less than about 5% of non-GPCR_X proteins. When the GPCR_X protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the GPCR_X protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of GPCR_X proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of GPCR_X proteins having less than about 30% (by dry weight) of chemical precursors or non-GPCR_X chemicals, more preferably less than about 20% chemical precursors or non-GPCR_X chemicals, still more preferably less than about 10% chemical precursors or non-GPCR_X chemicals, and most preferably less than about 5% chemical precursors or non-GPCR_X chemicals.

Biologically-active portions of GPCR_X proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the GPCR_X proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128) that include fewer amino acids than the full-length GPCR_X proteins, and exhibit at least one activity of a GPCR_X protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the GPCR_X protein. A biologically-active portion of a GPCR_X protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native GPCR_X protein.

In an embodiment, the GPCR_X protein has an amino acid sequence shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48,

50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128. In other embodiments, the GPCR_X protein is substantially homologous to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128, and retains the functional activity of the protein of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the GPCR_X protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128, and retains the functional activity of the GPCR_X proteins of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman

and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins

The invention also provides GPCR_X chimeric or fusion proteins. As used herein, a GPCR_X "chimeric protein" or "fusion protein" comprises a GPCR_X polypeptide operatively-linked to a non-GPCR_X polypeptide. An "GPCR_X polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a GPCR_X protein (SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126 and 128), whereas a "non-GPCR_X polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the GPCR_X protein, *e.g.*, a protein that is different from the GPCR_X protein and that is derived from the same or a different organism.

Within a GPCR_X fusion protein the GPCR_X polypeptide can correspond to all or a portion of a GPCR_X protein. In one embodiment, a GPCR_X fusion protein comprises at least one biologically-active portion of a GPCR_X protein. In another embodiment, a GPCR_X fusion protein comprises at least two biologically-active portions of a GPCR_X protein. In yet another embodiment, a GPCR_X fusion protein comprises at least three biologically-active portions of a GPCR_X protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the GPCR_X polypeptide and the non-GPCR_X polypeptide are fused in-frame with one another. The non-GPCR_X polypeptide can be fused to the N-terminus or C-terminus of the GPCR_X polypeptide.

In one embodiment, the fusion protein is a GST-GPCR_X fusion protein in which the GPCR_X sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant GPCR_X polypeptides.

In another embodiment, the fusion protein is a GPCR_X protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of GPCR_X can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a GPCR_X-immunoglobulin fusion protein in which the GPCR_X sequences are fused to sequences derived from a member of the immunoglobulin protein family. The GPCR_X-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a GPCR_X ligand and a GPCR_X protein on the surface of a cell, to thereby suppress GPCR_X-mediated signal transduction *in vivo*. The GPCR_X-immunoglobulin fusion proteins can be used to affect the bioavailability of a GPCR_X cognate ligand. Inhibition of the GPCR_X ligand/GPCR_X interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the GPCR_X-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-GPCR_X antibodies in a subject, to purify GPCR_X ligands, and in screening assays to identify molecules that inhibit the interaction of GPCR_X with a GPCR_X ligand.

A GPCR_X chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional

techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A GPCR_X-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the GPCR_X protein.

GPCR_X Agonists and Antagonists

The invention also pertains to variants of the GPCR_X proteins that function as either GPCR_X agonists (*i.e.*, mimetics) or as GPCR_X antagonists. Variants of the GPCR_X protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the GPCR_X protein). An agonist of the GPCR_X protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the GPCR_X protein. An antagonist of the GPCR_X protein can inhibit one or more of the activities of the naturally occurring form of the GPCR_X protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the GPCR_X protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the GPCR_X proteins.

Variants of the GPCR_X proteins that function as either GPCR_X agonists (*i.e.*, mimetics) or as GPCR_X antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the GPCR_X proteins for GPCR_X protein agonist or antagonist activity. In one embodiment, a variegated library of GPCR_X variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of GPCR_X variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a

degenerate set of potential GPCR_X sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of GPCR_X sequences therein. There are a variety of methods which can be used to produce libraries of potential GPCR_X variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential GPCR_X sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

Polypeptide Libraries

In addition, libraries of fragments of the GPCR_X protein coding sequences can be used to generate a variegated population of GPCR_X fragments for screening and subsequent selection of variants of a GPCR_X protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a GPCR_X coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S₁ nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the GPCR_X proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of GPCR_X proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble

mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify GPCR_X variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

5 **Anti-GPCR_X Antibodies**

Also included in the invention are antibodies to GPCR_X proteins, or fragments of GPCR_X proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such
10 antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab}, F_{ab}' and F_{(ab)2} fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light
15 chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated GPCR_X-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for
20 polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length
25 protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

30 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of GPCR_X-related protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the huma GPCR_X-related

protein sequence will indicate which regions of a GPCR-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols,

polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

5 The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be
10 immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (*The Scientist*, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

15 **Monoclonal Antibodies**

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of
20 the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse,
25 hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or
30 a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell

(Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia.

Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures

such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human

immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein.

Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13

(1994)); Fishwild et al, (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that

contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

- 5 In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

10 **F_{ab} Fragments and Single Chain Antibodies**

- According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective
- 15 identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab)₂} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)₂} fragment; (iii) an
- 20 F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Bispecific Antibodies

- Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that
- 25 have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

- Methods for making bispecific antibodies are known in the art. Traditionally, the
- 30 recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas)

produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

5 Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of
10 the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

 According to another approach described in WO 96/27011, the interface between a
15 pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or
20 similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

 Bispecific antibodies can be prepared as full length antibodies or antibody fragments
25 (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite
30 to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB

derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen.

Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active

toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of a GPCR protein is facilitated by generation of hybridomas that bind to the fragment of a GPCR protein possessing such a domain. Thus, antibodies that are specific for a desired domain within a

GPCRX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-GPCR_X antibodies may be used in methods known within the art relating to the localization and/or quantitation of a GPCR_X protein (*e.g.*, for use in measuring levels of the GPCR_X protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for GPCR_X proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-GPCR_X antibody (*e.g.*, monoclonal antibody) can be used to isolate a GPCR_X polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-GPCR_X antibody can facilitate the purification of natural GPCR_X polypeptide from cells and of recombinantly-produced GPCR_X polypeptide expressed in host cells. Moreover, an anti-GPCR_X antibody can be used to detect GPCR_X protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the GPCR_X protein. Anti-GPCR_X antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

GPCRX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a GPCR_X protein, or derivatives, fragments, analogs or

homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the

design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., GPCR

5 proteins, mutant forms of GPCR proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of GPCR proteins in prokaryotic or eukaryotic cells. For example, GPCR proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in
10 Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli*
15 with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the
20 recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors
25 include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc
30 (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the GPCR_X expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). Alternatively, GPCR_X can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43:

235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477),
5 pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3:
10 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense
15 to GPCR_X mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of
20 a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.*, Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

25 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either
30 mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, GPCR_X protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells

(such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding GPCR_X or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) GPCR_X protein. Accordingly, the invention further provides methods for producing GPCR_X protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding GPCR_X protein has been introduced) in a suitable medium such that GPCR_X protein is produced. In another embodiment, the method further comprises isolating GPCR_X protein from the medium or the host cell.

Transgenic GPCR_X Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which GPCR_X protein-coding sequences have been

introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous GPCR_X sequences have been introduced into their genome or homologous recombinant animals in which endogenous GPCR_X sequences have been altered. Such animals are useful for studying the function and/or activity of GPCR_X protein and for identifying and/or evaluating modulators of GPCR_X protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous GPCR_X gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing GPCR_X-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The huma GPCR_X cDNA sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the huma GPCR_X gene, such as a mouse GPCR_X gene, can be isolated based on hybridization to the huma GPCR_X cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the GPCR_X transgene to direct expression of GPCR_X protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for

production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the GPCR_X transgene in its genome and/or expression of GPCR_X mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding GPCR_X protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a GPCR_X gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the GPCR_X gene. The GPCR_X gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127), but more preferably, is a non-human homologue of a human GPCR_X gene. For example, a mouse homologue of human GPCR_X gene of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 can be used to construct a homologous recombination vector suitable for altering an endogenous GPCR_X gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous GPCR_X gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous GPCR_X gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous GPCR_X protein). In the homologous recombination vector, the altered portion of the GPCR_X gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the GPCR_X gene to allow for homologous recombination to occur between the exogenous GPCR_X gene carried by the vector and an endogenous GPCR_X gene in an embryonic stem cell. The additional flanking GPCR_X nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g.*, Thomas, *et al.*, 1987. *Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which

the introduced GPCR_X gene has homologously-recombined with the endogenous GPCR_X gene are selected. *See, e.g., Li, et al., 1992. Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g., a mouse*) to form aggregation chimeras. *See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152.* A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.,* by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al., 1997. Nature* 385: 810-813. In brief, a cell (*e.g., a somatic cell*) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.,* through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g., the somatic cell*) is isolated.

Pharmaceutical Compositions

The GPCR_X nucleic acid molecules, GPCR_X proteins, and anti-GPCR_X antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration,

suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a GPCR_X protein or anti-GPCR_X antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar

nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to

produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express GPCR_X protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect GPCR_X mRNA (*e.g.*, in a biological sample) or a genetic lesion in a GPCR_X gene, and to modulate GPCR_X activity, as described further, below. In addition, the GPCR_X proteins can be used to screen drugs or compounds that modulate the GPCR_X protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of GPCR_X protein or production of GPCR_X protein forms that have decreased or aberrant activity compared to GPCR_X wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-GPCR_X antibodies of the invention can be used to detect and isolate GPCR_X proteins and modulate GPCR_X activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

Screening Assays

5 The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to GPCR_X proteins or have a stimulatory or inhibitory effect on, *e.g.*, GPCR_X protein expression or GPCR_X protein activity. The invention also includes compounds identified in the screening assays described
10 herein.

 In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a GPCR_X protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library
15 methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small
20 molecule libraries of compounds. *See, e.g.*, Lam, 1997. *Anticancer Drug Design* 12: 145.

 A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological
25 mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

 Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678;
30 Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of GPCR_X protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a GPCR_X protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the GPCR_X protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the GPCR_X protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of GPCR_X protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds GPCR_X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a GPCR_X protein, wherein determining the ability of the test compound to interact with a GPCR_X protein comprises determining the ability of the test compound to preferentially bind to GPCR_X protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of GPCR_X protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the GPCR_X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate

the activity of GPCR_X or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the GPCR_X protein to bind to or interact with a GPCR_X target molecule. As used herein, a "target molecule" is a molecule with which a GPCR_X protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a GPCR_X interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A GPCR_X target molecule can be a non-GPCR_X molecule or a GPCR_X protein or polypeptide of the invention. In one embodiment, a GPCR_X target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound GPCR_X molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with GPCR_X.

Determining the ability of the GPCR_X protein to bind to or interact with a GPCR_X target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the GPCR_X protein to bind to or interact with a GPCR_X target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca²⁺, diacylglycerol, IP₃, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a GPCR_X-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a GPCR_X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the GPCR_X protein or biologically-active portion thereof. Binding of the test compound to the GPCR_X protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the GPCR_X protein or biologically-active portion thereof with a known compound which binds GPCR_X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a GPCR_X protein, wherein determining the ability of the test compound to interact with

a GPCR_X protein comprises determining the ability of the test compound to preferentially bind to GPCR_X or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting GPCR_X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the GPCR_X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of GPCR_X can be accomplished, for example, by determining the ability of the GPCR_X protein to bind to a GPCR_X target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of GPCR_X protein can be accomplished by determining the ability of the GPCR_X protein further modulate a GPCR_X target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the GPCR_X protein or biologically-active portion thereof with a known compound which binds GPCR_X protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a GPCR_X protein, wherein determining the ability of the test compound to interact with a GPCR_X protein comprises determining the ability of the GPCR_X protein to preferentially bind to or modulate the activity of a GPCR_X target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of GPCR_X protein. In the case of cell-free assays comprising the membrane-bound form of GPCR_X protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of GPCR_X protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either GPCR_X protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to

accommodate automation of the assay. Binding of a test compound to GPCR_X protein, or interaction of GPCR_X protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-GPCR_X fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or GPCR_X protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of GPCR_X protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the GPCR_X protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated GPCR_X protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with GPCR_X protein or target molecules, but which do not interfere with binding of the GPCR_X protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or GPCR_X protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the GPCR_X protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the GPCR_X protein or target molecule.

In another embodiment, modulators of GPCR_X protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of GPCR_X mRNA or protein in the cell is determined. The level of expression of GPCR_X mRNA or protein in the presence of the candidate compound is compared to the level of expression of

GPCRX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of GPCRX mRNA or protein expression based upon this comparison. For example, when expression of GPCRX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of GPCRX mRNA or protein expression. Alternatively, when expression of GPCRX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of GPCRX mRNA or protein expression. The level of GPCRX mRNA or protein expression in the cells can be determined by methods described herein for detecting GPCRX mRNA or protein.

In yet another aspect of the invention, the GPCRX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with GPCRX ("GPCRX-binding proteins" or "GPCRX-bp") and modulate GPCRX activity. Such GPCRX-binding proteins are also likely to be involved in the propagation of signals by the GPCRX proteins as, for example, upstream or downstream elements of the GPCRX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for GPCRX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a GPCRX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with GPCRX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the
5 corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are
10 described in the subsections, below.

Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is
15 called chromosome mapping. Accordingly, portions or fragments of the GPCR_X sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, or fragments or derivatives thereof, can be used to map the location of the GPCR_X genes, respectively, on
20 a chromosome. The mapping of the GPCR_X sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, GPCR_X genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the GPCR_X sequences. Computer analysis of the
25 GPCR_X sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the GPCR_X sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals
30 (*e.g.*, human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in

which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. *See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924.* Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the GPCR sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, *see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES* (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such

data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the GPCR_X gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing

The GPCR_X sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the GPCR_X sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The GPCR_X sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater

degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining GPCR_X protein and/or nucleic acid expression as well as GPCR_X activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant GPCR_X expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with GPCR_X protein, nucleic acid expression or activity. For example, mutations in a GPCR_X gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to

thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with GPCR_X protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining GPCR_X protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of GPCR_X in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of GPCR_X in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting GPCR_X protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes GPCR_X protein such that the presence of GPCR_X is detected in the biological sample. An agent for detecting GPCR_X mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to GPCR_X mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length GPCR_X nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125 and 127, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to GPCR_X mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting GPCR_X protein is an antibody capable of binding to GPCR_X protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a

detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect GPCR_X mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of GPCR_X mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of GPCR_X protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of GPCR_X genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of GPCR_X protein include introducing into a subject a labeled anti-GPCR_X antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting GPCR_X protein, mRNA, or genomic DNA, such that the presence of GPCR_X protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of GPCR_X protein, mRNA or genomic DNA in the control sample with the presence of GPCR_X protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of GPCR_X in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting GPCR_X protein or mRNA in a biological sample; means for determining the amount of GPCR_X in the sample; and means for comparing the amount of GPCR_X in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect GPCR_X protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant GPCR_X expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with GPCR_X protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant GPCR_X expression or activity in which a test sample is obtained from a subject and GPCR_X protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of GPCR_X protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant GPCR_X expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant GPCR_X expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant GPCR_X expression or activity in which a test sample is obtained and GPCR_X protein or nucleic acid is detected (*e.g.*, wherein the presence of GPCR_X protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant GPCR_X expression or activity).

The methods of the invention can also be used to detect genetic lesions in a GPCR_X gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a GPCR_X-protein, or the misexpression of the GPCR_X gene. For example,

such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a GPCR_X gene; (ii) an addition of one or more nucleotides to a GPCR_X gene; (iii) a substitution of one or more nucleotides of a GPCR_X gene, (iv) a chromosomal rearrangement of a GPCR_X gene; (v) an alteration in the level of a messenger RNA transcript of a GPCR_X gene, (vi) aberrant modification of a GPCR_X gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a GPCR_X gene, (viii) a non-wild-type level of a GPCR_X protein, (ix) allelic loss of a GPCR_X gene, and (x) inappropriate post-translational modification of a GPCR_X protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a GPCR_X gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the GPCR_X-gene (*see*, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682).

This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a GPCR_X gene under conditions such that hybridization and amplification of the GPCR_X gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwoh, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q β Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques

well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a GPCR_X gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in GPCR_X can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotide probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in GPCR_X can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the GPCR_X gene and detect mutations by comparing the sequence of the sample GPCR_X with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (*see, e.g.*, Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (*see, e.g.*, PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the GPCR_X gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. *See, e.g., Myers, et al., 1985. Science 230: 1242.* In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type GPCR_X sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295.* In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in GPCR_X cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662.* According to an exemplary embodiment, a probe based on a GPCR_X sequence, *e.g., a wild-type GPCR_X sequence*, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g., U.S. Patent No. 5,459,039.* In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in GPCR_X genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79.* Single-stranded DNA fragments of sample and control GPCR_X nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids

varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. *See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.*

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g., Myers, et al., 1985. Nature 313: 495.* When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. *See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.*

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448*) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g., Prossner, 1993. Tibtech. 11: 238*). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1.* It is anticipated that in certain embodiments

amplification may also be performed using *Taq* ligase for amplification. *See, e.g.*, Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a GPCR_X gene.

10 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which GPCR_X is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

15 **Pharmacogenomics**

Agents, or modulators that have a stimulatory or inhibitory effect on GPCR_X activity (*e.g.*, GPCR_X gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of GPCR_X protein, expression of GPCR_X nucleic acid, or mutation content of GPCR_X genes in

an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.

5 See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions
10 can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major
15 determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are
20 expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor
25 metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to
30 CYP2D6 gene amplification.

Thus, the activity of GPCR_X protein, expression of GPCR_X nucleic acid, or mutation content of GPCR_X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition,

pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a GPCR_X modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of GPCR_X (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase GPCR_X gene expression, protein levels, or upregulate GPCR_X activity, can be monitored in clinical trials of subjects exhibiting decreased GPCR_X gene expression, protein levels, or downregulated GPCR_X activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease GPCR_X gene expression, protein levels, or downregulate GPCR_X activity, can be monitored in clinical trials of subjects exhibiting increased GPCR_X gene expression, protein levels, or upregulated GPCR_X activity. In such clinical trials, the expression or activity of GPCR_X and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including GPCR_X, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates GPCR_X activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of GPCR_X and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of GPCR_X or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a GPCR_X protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the GPCR_X protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the GPCR_X protein, mRNA, or genomic DNA in the pre-administration sample with the GPCR_X protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of GPCR_X to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of GPCR_X to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant GPCR_X expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright hereditary osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with

- 5 Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (*i.e.*, due to a heterologous insertion within the
- 10 coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or
- 15 antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity

20 may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

- Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or
- 25 peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot
- 30 blots, *in situ* hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant GPCR_X expression or activity, by administering to the subject an agent that modulates GPCR_X expression or at least one GPCR_X activity. Subjects at risk for a disease that is caused or contributed to by aberrant GPCR_X expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the GPCR_X aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of GPCR_X aberrancy, for example, a GPCR_X agonist or GPCR_X antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating GPCR_X expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of GPCR_X protein activity associated with the cell. An agent that modulates GPCR_X protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a GPCR_X protein, a peptide, a GPCR_X peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more GPCR_X protein activity. Examples of such stimulatory agents include active GPCR_X protein and a nucleic acid molecule encoding GPCR_X that has been introduced into the cell. In another embodiment, the agent inhibits one or more GPCR_X protein activity. Examples of such inhibitory agents include antisense GPCR_X nucleic acid molecules and anti-GPCR_X antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a GPCR_X protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates

(e.g., up-regulates or down-regulates) GPCR_X expression or activity. In another embodiment, the method involves administering a GPCR_X protein or nucleic acid molecule as therapy to compensate for reduced or aberrant GPCR_X expression or activity.

Stimulation of GPCR_X activity is desirable in situations in which GPCR_X is abnormally downregulated and/or in which increased GPCR_X activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

10 Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

The GPCR_X nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's disease, Parkinson's disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

As an example, a cDNA encoding the GPCR_X protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have

efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's disease, Parkinson's disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

5 Both the novel nucleic acid encoding the GPCR_X protein, and the GPCR_X protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies which

10 immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

15

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC016787_A	1/2	AATGAAGAGAAAGAACTTCACAGAAGTGCAGAAATTCATTTTCTTGGGATTTTCT AGCTTTGGAAAGCATCAGATAAACCTCTTTGTGGTTTTCCTAACTGTCTACATTT TAACTCTGGTTGCTAACATCATCATTTGTGACTATCATCTGCATTGACCATCATCT CCACACTCCCATGTATTTCTTCTAAGCATGCTGGCTAGTTTCAGAGACGGTGTAC ACACTGGTCAATTGTGCCACGAATGCTTTTGAGCCTCATTTTTCATAACCAACCTA TCTCCTTGGCAGGCTGTGCTACACAAATGTTCTTTTGTATCTTGGCCACTAAT AATTGCTTCTGCTTACTGCAATGGGTATGACCGCTATGTGCCATCTGCAGAC CCCTGAGATACACTGTCAATGAGCAAGGACTATGTGCCAGCTGGTGTG GGTCTTTGGCATTGGTCTGACTATGGCAGTCTCCATGTGACAGCCATGTTCAA TTTGCCGTTCTGTGGCACAGTGGTAGACCATTCTTTTGTGACATTTACCCAGTC ATGAAACTTTCTTGCAATGATACCATATCAATGAGATAATAAATATGGTGTA GTTCAATTTGTGATTTTGTGCCCATAGCCCTGATATTTATCTCTATGTCCTTGT ATCTCTCCATCCTTCAAATTGCCCTCAGCTGAGGCCGGAAGAAGACCTTTGCCA CCTGTGCTCCCACTCACTGTGGTTATTTGTCCACTGTGGCTGTGCCCTCCATTGCC TACCTCAAGCCGAAGTCAGAAAGTTCAATAGAAAAAGACCTTGTCTCTCAGTG ACGTACACCATCATCACTCCCTTGTGTAACCTGTGTTTACAGTCTGAGAAACA AGGAGGTAAGGATGCCCTATGCAGAGTTGTGGCAGAAATATTTCTTAATGGA TTGGATTATTTCAATTAAGAGACCATTAGCCCA	MKRKNFTIEVSEFELGFSS FGKHQITLFFVFLTVYILT LVANIIIVTICIDHHLHTP MYFFLSMLASSETVYTLV IVPRMLLSLIFHNQPISLA GCATQMEFFVILATNNCF LLTAMGYDRYVAICRPLR YTVIMSKGLCAQLVCGSF GIGLTMAVLHVTAMFNL PFCGTVVDHFFCDIYPVM KLSCIDTTINEINYGVSSF VIFVPIGLIFISYVLVISSIL QIASAEGRKKTFATCVSH LTVVIVHCGCASIAYLKP KSESSIEKDLVLSVYTIIT PLLNPVVYSLRNKEVKDA LCRVVGRNIS

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC011517_A	3/4	TATCCATGCCATGTCAGAACATAGCATCATATCTGAATTAAACCTCTTTGGCTT CTCAGCCTTCCCCAGCACTCTGCCATCTTGTTCCTGCTGTACCTCCTGATGT TCCTGTTACATATGCTGGCAACCTTCTCATCATGCCCCAACATCTGGATTGAACA CAGACTCCACACACCCCATGTCCTCTTCTGTGCAACCTCTCCGTTCTGAGATT CTGTTCACTGTTGCCATCAACCCCTCGCATGCTGGCTGATCTGCTTTCCACCCATC ATTCCATCACTTTGTGGCTTGTGCCAACCCAGATGTTCTTCTCCTTCATGTTTGGC TTCACTCACTCCTTCTTCTGCTCATGAGCCCCCGTGACTGTGCCCATCTTGTG CCACCCACTGCGTTACATGCTCATGAGCCCCCGTGACTGTGCCCATCTTGTG GCCTGTACCTGGCTGGTGGCTCAGTCAATGGGATGATGGTGACACGATAGTT TTCCACCTCACTTCTGTTGGCTGTGAAACAAAGACATCATCTGTCATCATGGGTGT TTCCCTCTTGAAAGTTGGCTGTGAAACAAAGACATCATCTGTCATCATGGGTGT ATGCTGTTGTGTACAGCCCTGATAGGCTGTTATTCCTCATCATCCTCTCCT ATGCTTCTACGTGTGTATCCACCTCACTGTGGTGGTCAAGCCGACACTATAGTTT GACATTTTCTACGTGTGTATCCACCTCACTGTGGTGGTCAAGCCGACACTATAGTTT GCCTCCTTTATCTACCTCAAGCCCAAGGCCCTCCATCTATGTACAGTGACGCT TGATGGCCACCACTATCTGTCTTCAACCCCTTCTTAGCCCAATCATTTTCAGC CTAAGGAACAAGGAGCTGAAGAAATGCCATAAATAAAACCTTTTACAGAAAAATTC TGTCCTCCAAAGTTCTTGAGCGCCA	MPSONYSIISEFNLFGFA FPQHLLPILFLYLLMFLF TLLGNLLMATIWIEHRLH TPMYLFLCTLSVSEILFTV AITPRMLADLLSTHHSITF VACANQMFSSFMFGFTHS FLLLVMGYDRYVAICHPL RYNVLMSPRDCAHLVAC TWAGGSVMGMMVTITVF HLTFCGSNVIIHFFCHVL SLLKLACENKTSSVIMGV MLVCVTALIGCLFLILSY VFIVAAILRIPSAEGRHKT FSTCVSHLTVVVVTTHYSFA SFIYLPKPKGLHSMYS DAL MATTYTVFTPFLSPIFSLR NKLKNAINKNFYRKFCP PSS

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC008620_B	5/6	CCATGGAGACGTGGTGAACACGCTCTACACAGATGGCTTCTTCTCTTAGGCAT CTTCTCCACAGTACTGCTGACCTTGCTCTCTCCGTGTTATGGCGTCTTCA CAGTGGCCCTCTGTGGAAATGTCCCTCCTCATCTTCTCATCTACATGGACCCCTCA CCTTCACACCCCATGTACTTCTTCCCTCAGCCAGCTCTCCCTCATGGACCTCATGT TGGTCTGTACCAATGTGCCAAGATGGCAGCCAACTTCTGTCTGGCAGGAAGT CCATCTCCTTTGTGGCTGTGGCATAACAAATGGCCCTCTTGTCTGTCTTGTGGG ATCTGAGGGGCTCTTGTCTGGACTCATGGCTTATGACCGCTATGTGCCATTAGC CACCCACTTCACTATCCCATCCTCATGAATCAGAGGGTCTGTCTCCAGATTACTG GGAGCTCTGGGCCCTTGGGATAATCGATGGCTTGATCCAGATGGTGGTAGTAA TGAATTTCCCTACTGTGGCTTGAGGAAGGTGAACCATTTCTTCTGTGAGATGCT ATCCTTGTGTAAGCTGGCTGTGTAGACACATCCCTGTTTGAGAAAGTGATATT GCTTGTGTCTTCTATGCTTCTTCCATTCCTCATCATCGTGGCTCCTCATGC TCACATTCTAGGGACTGTGTGCAATGCACTGTCTCAGGCCCTGGAAGAGGC CCTGGCCACCTGCTCCTCCACCTGACAGCTGTCACTTCTTATGGGGCAGCC ATGTTTCATCTACCTGAGGCCTAGGCACTACCGGGCCCCAGCCATGACAAAGGTG GCCCTATCTTCTACACGGTCTTACTCCCATGTCAACCCCTCATTTACAGCTT GAGGAACAGGGAGGTGATGGGGCCTGAGGAAGGGGCTGGACCGCTGCAGGA TCGGCAGCCAGCACTGAACCCAGGGCATCCAGTGCCTGGCTCTGCCATCTCTTAG CTCCAGGGAT	METWVNQSYTDGFFLLGI FSHSTADLVFSVVMVAF TVALCGNVLLFLIYMDP HLHTPMYFFLSQLSLMDL MLVCTNVPKMAANFLSG RKSISFVCGCIQIGLFVCL VGSEGLLLGLMAYDRYV AISHPLHYPIILMNQRVCL QITGSSWAFGIIDGLIQMV VVMNFPYCGLRKVNHF CEMLSLKLACVDTSLFE KVIFACCVFMLLPFSIIV ASYAHILGTVLQMHSAQ AWKKALATCSSHLTAVT LFYGAAAFIYLRPRHYRA PSHDKVASIFYTVLTPML NPLIYSLRNREVVMGALRK GLDRCRIGSQH

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC011711_C	7/8	CTCATAATCTCCCTCATTATGTCTGTCTCAATACTCCGAAGTCAAGCTTTTCCTT CTGATTGGGATCCAGGACTGGACATGCCCACATTTGGTTCTCCATCCCCATTT GCCTCATGTACCTGCTTGCCATCATGGCAACTGCACCATTCCTTTATTATAAA GACAGAGCCCTCGCTTCAATGAGCCCATGTATTATTCTTGCCATGTTGGCTGTC TCTGACATGGGCTGTCCCTCTCCCTCCCTTCCCTACCATGTTGAGGGTCTTCTTGTT CAATGCCATGGGAATTCACCTAATGCCTGCTTGTCTCAAGAAATTCCTTCATTCAT GGATTCACTGTCAATGGAATCCTCAGTACTTCTAATATATGTCTTTGGACCGCTTC TTGCCATTCACAATCCCTTAAGATACAGTTCTATCCTCACTAGCAACAGGGTTGC TAAATGGGACTTATTTAGCCATTAGGAGCATCTCTTAGTGATCCATTCCCT TTCACCTTAAGGAGATTAAATATTGTCAAAAGAAATCTTCTTCTCACTCATACT GTCTTCATCAGGATACCATGAAGCTGGCTGTCTGACAAACAGACCAATGTCAT CTATGGCTTCTTCATTGCTCTGTGACTATGCTGGACTTGGCAGTGTGTTTGT CTTATGTGCTGATCTTGAAGACTATACCTAGCATCTGTGCTGTCTCACTTCTATGTG TAAGGCCCTAAATACCTGTGTCTCCACATCTGTGCTGTCTCACTTCTATGTG CCCATCATCACCCCTGGCTGCCATGCATCACTTGGCAAGCAAAAGCCCTCTTG TTGTGATCCTTATTGCAGATATGTTCTTGTGCTGGCGCCCTTATGAACCCCAT GTGTACTGTGTAAGAGACTCGACAAATCTGGGAGAGATCTTGGGGAAGTTGCTT AATGTATGTGGGAGATAAGAACTTGAACAATTAG	MSVLNNSEVKLFLLIGIPG LEHAHIWFSIPICLMYLLA IMGNCTILFIKTEPSLHEP MYYFLAMLAVSDMGLSL SSLPTMLRVFLFNAMGISP NACFAQEFFIHHGFTVMES SVLLIMSLDRFLAIHNPLR YSSILTSNRVAKMGLILAI RSILLVIPFPFILLRLKYC QKNLLSHSYCLHQDTMK LACSDNKTNIYGGFFIALC TMLDLALIVLSYVLILKTI LSIASLAERLKAALNTCVSH ICAVLTFYVPIITLAAMHH FAKHKSPLVVILIADMFL VPPLMNPVYCVKTRQIW EKILGKLLNVCGR

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG55980-01	9/10	CTCATATCTCCCTCATTATGTCTGTTCTCAATAACTCGAAGTCAAGCTTTTCCCTT CTGATTGGATCCAGGACTGGAACATGCCACATTGGTTCTCCATCCCCCATTT GCCTCATGTACCTGCTTGCCATCATGGGCAACTGCACCATTCCTTTATTATAAA GACAGAGCCCTCGCTTCATGAGCCCATGTATTATTCCTTGCCATGTTGGCTGTC TCTGACATGGGCTGTCCTCTCCTCCCTTCCCTACCATGTTGAGGGTCTTCTTGTT CAATGCCATGGGAATTCACCTAATGCCTGCTTGTCTCAAGAAATCTTCAATTCAT GGATTCACTGTCAATGGAATCCTCAGTACTTCTAAATTAATGTTTGGACCGCTTC TTGCCATTCACAATCCCTTAAGATACAGTTCTATCTCCTACTAGCAACAGGGTTGC TAAATGGGACTTATTTAGCCATTAGGAGCATTCCTTAGTGATTCATTTCCC TTCACCTTAAGGAGATTAAATATTTGTCAAAAGAAATCTTCTTCTCACTCATACT GTCTTCATCAGGATACCATGAAGCTGGCTGCTGACAAAGACCAATGTCTAT CTATGGCTTCTTCATTGCTCTGTACTATGCTGGACTTGGCACTGATTGTTTGT CTTATGTGCTGATCTTGAAGACTATACCTAGCATCTGTGCTGTGCTCACCTTCTATGTG TAAGGCCCTAAATACCTGTGCTCTCCACATCTGTGCTGTGCTCACCTTCTATGTG CCCATCATCACCCCTGGCTGCCATGCATCAGTCTTGCCAAAGCAAAAGCCCTCTTG TTGTGATCCTTATTGCAGATATGTTCTTGTGTCGCCCTTATGAACCCCATTT GTGTACTGTGTAAGACTCGACAAATCTGGGAGAAAGATCTTGGGGAAGTTGCTT AATGTATGTGGGAGATAAGAACTTGAACAATTAG	MSVLNNSEVKFLLLIGIPG LEHAHIWFSIPICLMYLLA IMGNCITLFIKTEPSLHEP MYYFLAMLAVSDMGLSL SSLPTMLRVFLFNAMGISP NACFAQEFFHGHFTVMES SVLLIMSLDRFLAIHNPLR YSSILTSNRVAKMGLILAI RSILLVIPFPFTLRLKYC QKNLLSHSYCLHQDTMK LACSDNKTNIYGVFFIALC TMLDLALIVLSYVLILKTI LSIASLAERLKALNTCVSH ICAVLTFYVPIITLAAMHH FAKHKSPLVVLADMFLL VPPLMNPVYCVKTRQIW EKILGKLLNVCGR

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC009642_A	11/12	CTCATGATTGAGCCTATGGCGTCACCCGACCAAGCTCCACTGTCCCAGTCTCTG AATTCCTCTCACTGCTTCCCAACTTCCAGAGTTGGCAGCACTGGCTCTCCCT GCCCCAGCCTTCTCTCTCTGCGCATGGGAGCTAACACACCCCTCCTGATC ACCATCCAGCTGGAGCCTCTCTGACACCGCCCTGTACTACCTGCTCAGCCTCC TCTCCCTGCTGGACATCGTCTCTGCTCACCCTCATCCCCAAGTCTCTGGCCAT CTTCTGGTATGATCTTAGGTCGATCAGCTTCCCTGCTGCTTCCCTCCAGATGTTC ATCATGAACAGTTTCTCCCATGGAGTCTGACGTTTATGGTCATGGCCTATG ACCGTTATGTGGCCATCTGCCACCCACTGCGGTACCCATCCATCACTCAATCA ATTTGTGCCAAAGCTAGTGCTCTTCAATTGTGGTGCGGAATGCGCTTCTTACTGCA CCCATTCCTATCCTCACTTCCCTGCTCCATTACTGTGGGAAATGTCATTGAGA ACTGCATCTGTGCCAACTTGTCTGTGCCAGGCTCTCCTGTGATAATTCAACCCT TAACAGAACTCTACCAATTTGTGGCTGGTGGACCTTGTGGGCTCAGATTATTC CTCATCTTCTCTTACACCTTCACTTAAGAGCTGTGCTTAGATTCAAAGCAG AGGGGGCGCAGTGAAGGCCCTGAGCAGTGTGGCTCCCACTTCACTCCTCATT TTTCTTCAGCACCATCTGCTGCTGTTGTGGTGTGACAAACGTGGCCAGAAAGAA GGTCCCCATGGACATCCTGATCCTGCTGAACGCTCTTCACTACCTTATTCCTCCT GCGTTGAACCCCTATTGTGTATGGGGTTTCGGACCAAGAGATAAAACAGGGAATT CAGAACTTACTGCAGAGAGGGAGGTGAATAT	MIQPMASPSNSTVPVSEF LLTCFPNFQSWQHWLSLP LSLLFLAMGANTLLITI QLEASLHQPLYLLSLLSL LDIVLCLTVIPKVLAFWY DLRSISFPACFLQMFIMNS FLPMESCTFMVMAYDRY VAICHPLRYPSTITNQFVA KASVFIVVRNALLTAPIPI LTSLLLHYCGENVENCICA NLSVSRLSCDNFTLNRIY QFVAGWTLLGSDLFLIFL SYTFILRAVLRKAEAGAA VKALSTCGSHFELILFFSTI LLVVVLTVNVARKKVPMD ILLLNLVHLHLPALNPV YGVRTKEIKQGIQKLLQR GR

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL049739_A	13/14	TGCAAAACACCTCCATGGTGACTGAGTTCTTCTCTCGGCTTCTCCACCTGGCC GACCTCCAGGGCTTGCTCTCTGTCTTCTCACTATCTACCTGCTGACCGTGCC AGGCAATTCTCTCATTTGTGCTGCTCCACTGATGCTGCCCTCCAGTCCCT ATGTACTTCTTCTCGGCACCCCTCTCGGCTTGAGATTGGCTATACGTCTGTCA CGGTCCCTCTGCTCACTTCAACACCTCTTACTGGCCGCGCCACATCTCTCGCTC TGATGTGCTCTCCAGATGTTCTTCTCTCTTCTTGGCGCCACGAGTGCTGC CTCCTGGCAGCCATGGCTATGACCGCTATGACGCCATCTGTGAACCCCTCCGCT ACCCACTGCTGCTGAGCCACCGGTGTGTCTACAGCTAGCTGGTGGCGTGCGG CCTGTGGGTGCTGGTGGGCTGGGCCACACCCCTTCTATCTCTTGTGCCCTT CTGGGCCCCAATACCATCCCGAGTTCTTCTGTGAGATCCAGCTGTCTGCAG CTGGTATGTGGAGACACCTCGCTTAATGAATGCAGATTATCTGGCAACAGCC CTCCTCATCTCTGCCCCCTTTGGCTCATCTGGGCTCTACGGGCGTATCCTCGT TACCATCTTCCGGATCCCATCTGTGGGGCCGCCAAGGCTTCTCCACCTGC TCCTCCACCTGATCGTGTCTCCCTCTTCTATGGCACCGCACTCTTATCTATAT TCGCCCTAAGGCCAGTACGATCCGGCCACTGACCCCTCTGGTGTCCCTCTCTAT GCTGTGGTCAACCCCATCTCTCAACCCCATCTACAGCCTGGGGAACACAGAGG TCAAAGCTGCCCTAAAGAGAACCATCCAGAAACGGGTGCCTATGGAGATTGTGAA AAGGGGGCGGATA	MVTEFLLLGFSLHADLQ LLFSVFLTYLLTVAGNFL IVVLVSTDAALQSPMYFF LRTLSTALEIGYTSVTVPLL LHLLTGRRHISRSGCAL QMFFLFFGATECCLLAA MAYDRYAAICEPLRYPLL LSHRVCLQLAGSAWACG VLVGLGHTPPFISLPFCGP NTIPQFFCEIQPVQLVCG DTSNELQILATALLILCP FGLILGSYGRILVTIFRIPS VAGRRKAFSTCSSHLIV SLFYGTALFYIRPKASYD PATDPLVSLFYAVVTPILN PIIYSLRNTEVKAALKRTI QKTVPMEI

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG54281-02	17/18	AAAATGCTCAATTTACCGATGTGACAGAGTTCATTCTTTGGGGCTAACGAGCC GTCGAGAAATGGCAAGTTCTCTTCTTCATCATCTTTGTGGTCTACATCATCAC CATGGTGGCAATATCGGCATGATGGTGTAAATCAAGTCAGTCTCAGCTTAA CAACCCCATGTACTTTTCTCAGTCACCTTGTCATTTGTGTGATGTGGTCTTCTT CCAATGTCACCCCTAAATGTTGGAAAACCTGTTATCAGATAAAAAACAATTA CTTATGCTGTTGTTAGTACAGTGTCTTCTTCTTCATTGCTCTTGTCCATGTGGAA ATTTTATCTTGTCTGCGATGGCCCTTGTATAGATACATGGCAATTGGGAATCCTC TGCTTTATGGCAGTAAATGTCAAGGTTGTCTGTATTCGACTGATTACTTTCCC TTACATTTATGGTTTTCTGACGAGTCTGGCAGCAACATTATGGACTTACGGCTTG TACTTCTGTGGAAAAATTGAGATCAACCATTTCTACTGTGCAGATCCACCTCTCA TCAAAATGGCCTGTGCTGGACCTTTGTAAAAGAAATATACAATGATCATACTTGC CGGCATTAACTTCACATATTCCTGACTGTAAATATCATCTCTTACTTATTCATCC TCATTGCCATTCTGCGAATGCGCTCAGCAGAGGAAGGAGAGGCCCTTTTCCA CATGTGGTCCCATCTGACAGCTGTCAATATTTCTATGGTACTCTGATCTTCAT GTATCTCAGACGTCCACAGAGAGTCTGTGGAGCAGGGGAAGATGGTGGCTGT GTTCTATACACAGTGTATCCCATGTTGAATCCCATGATCTACAGTCTGAGGAAC AAGGATGTGAAAAAGGCCATGATGAAAGTGATCAGCAGATCATGTTAAACAAAA TAAAAATCAAAATTGATTAAATTTTATCTCTAT	MLNFTDVTEFILLGLTSR REWQVLFHFLVVIITM VGNIGMMVLKVSQNLN NPMYFFLSHLSFVDVWFS SNVTPKMLENLLSDKKT TVAGCLVQCFFIALVHV EIFILAAAMAFDRYMAIGN PLLYGSKMSRVVCIRLITF PYIYGFLTSLAATLWYTG LYFCGKIEINHFYCADPPL IKMACAGTFVKEYTMIL AGINFTYSLTVIHSYLFIL AILRMRSAGRQKAFSTC GSHLTAVIIFYGTLIFMYL RRPTEESVEQGMVAVF YTTVIPMLNPMIYSLRNK DVKKAMMKVISRSC

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG55744-01	19/20	GTGGACATGGAAGTGGGAAATTGCACCATCTGACTGAATTCATCTTGTGGGT TTCTCAGCAGATTCCAGTGGCAGCGATTCTATTGGAGTGTTCTGATGCTCT ATTGATAACCTTGTGAGGAAACATGACCTTGGTTATCTTAATCCGAACTGATTC CCACTTGCATACACCTATGTACTTTTTCATTGGCAATCTGTCTTTTGGATTCT GGTATACCTCTGTGTATACCCCAAAATCCTGGCCAGTTGTGTCTCAGAGATAA GCGCATTTCTTGGCTGGATGTGGGCTCAGCTGTTTTTCTCTGTGTAGCC TACACTGAATGCTATCTCTGGCAGCCATGGCATATGACCGCCCTCTGTACTGGCTGT GTAAACCATTTGCTTTATTCAGGTACCATGTCCACCGCCCTCTGTACTGGCTGT TGCTGGCTCTACATAGGAGGATTTTGAATGCCATAGCCCATCTGCCAATACA TTCCGCTGCAATTTTGTGGTAAAAATATCATTGACCACCTTTTCTGTGATGCAC CACCGTTGGTAAAAATGTCTGTACAGACACCCAGGCTACGAAAAGTCCTGC TTGGTGTGGTGGCTTCACAGTACTCTCCAGCATTCTTGCTATCCTGATTTCTTA TGTCACAATCCTCTGGCTATCTGAGATCCACTAGCTTCAGGAAGACACAAG GCATTCCTCCACCTGTCTCCACCTCATCTCAGTCACTGCTCTTCTATGGATCAT GTTGTTTATGTATTCAAGGCCTAGTTCCACCTACTCCCTAGAGAGGACAAAAGTA GCTGCTCTGTTCTACACCGTGATCAACCCACTGTCAACCCCTCTCATCTATAGCC TGAGAAACAAAAGATATCAAAGAGGCTTCAGGAAAGCAACACAGACTATACAAC CACAAACATGAA	MEVGNCTILTEFILLGFSA DSQWQPILFGVFLMLYLI TLSGNMTLVILRTDLSHLH TPMYFFIGNLSFLDFWYT SVYTPKILASCVSEDKRIS LAGCGAQLFSCVVAYTE CYLLAAMAYDRHAAICN PLLYSGTMTALCTGLVA GSYIGGFLNAIAHTANTF RLHFCGKNIIDHFFCDAPP LVKMSCTDTRVYEKVL GVVGFTVLSILAILISYV NILLAILRIHSASGRHKAF STCASHLISVMLFYGSLLF MYSRPSSTYSLERDKVAA LFYTVINPLNPLIYSLRN KDIKEAFRKAQTITPQT

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL365336_H	25/26	CTGTTACCACAAATTTATTGTGCAAAATGACTGCAAGAAACATGACAAACAATGAG TGGAATTCCTCATGGGTTCTCTGACAAACCATGAATTGCAGATCTTACAGGCT TTGCTGTTTTTGTGACATAACCTATTGGGCTCAGCAGGAACTTCATCATATTCA CCATCACAACACTGGACCCACAGCTCCAGTCTCCAAATGTAATTTTCTGAAGCA ACTTCCACTCTGGACCTCTCATCCCTCTCTGTCCACAGTTCCTCAGTAATGTTGCCA GTTCCCTGGCACGAAGTGGCTACATTTTCATATGGCAATGCATGCTGCAGATATT TTTCTTCACAGGTTTGGCCTGGAGTGAATGGCCACTCTCACAGTGAATGCTTAT GATCGCTATGTGGCCATCTGCCCTCCCACTGCACTATGAGGTCATAATGAGTCCCA GAAAGTGCACTTGGGCTGTGGCAGCTGTGTGGCTAAGTGGAGGTATCTCAGGAA CATTATTCACAGCAAGTACACTCTCTATCAGATTCTGTGGGACAAATATTCA CCAGTTCTTCTGTGATATCCCGCAATTGCTCAAGCTCTCCTGCTCTAATGATTACT TTGGAGTACTGGAAAGTGTCTACTTTTCATGTCTGTAAATGGCCTTTGCCTGTTGT GGGATTGCTTCTCTATGGCCAGATATTTCTACAGTTCTCAGGATGCCCTCT GCTGAAGGCCGATCTAAGGCTTCTCCACCTGCCTGCCCATCTCTTCGTTGTTT CAITTTTCTCTCAACAGGCAATTTGTGCTATCTTTTACACACTACTACCCCAACCTCA AACTGCTTTAGACCTCATGCTCTCTATCTTTTACACACTACTACCCCAACCTCA ACCTGTTATCTATAGTCTGAGAAATGAGTCCCTTGAAAGAGAGCACTAAAGAAAGT TACTGCTAAGTGAAGAATTCATTAGGAAAAAATGTTTGTCTATTTTAGT	MTARNMTTMSGFLLMGF SDNHELQILQALLFLTYL LGSAGNFIHTTLLDPQLQ SPMYVFLKQLSLDLSSL SVTPQYVASSLARSGYI SYGQCMLQIFFFTGLAWS EMATLTVMSYDRYVAIC LPLHYEVIMSPRKCTWAV AAVWLSGGISGTLFTAST LSIRFCGDKIIHQFFCDIPQ LLKLSCSNDYFGVLEVST FMSVMAFACFVGIAFSYG QIFSTVLRMPSAEGRSKV FSTCLPHLFVVSFFLSTGI CAYLKPTSDSPTALDLML SIFYTLLPPTLNPVIYSLRN ESLKRALKKLLLSEEFIRK KCLFYF

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL359352_F	27/28	CTGTTACCACAAATTATTGTCACAAATGACTGCAAGAAACATGACACAAATGAG TGGAATTCCTCTCATGGGTTCTCTGACAAACCATGAATTGCAGATCTTACAGGCT TTGCTGTTTTTGTGACATAACCTATTGGGCTCAGCAGGAACTTCATCATATCA CCATCACAACACTGGACCCACAGCTCCAGTCTCCAAATGTATTATTTCTGAAGCA ACTTCCACTCTGGACCTCTCATCCCTCTCTGTCCACAGTTCCCTCAGTATGTTGCCA GTTCCCTGGCAGCAAGTGCTACATTTTCATATGGCAATGCATGCTGCAGATATT TTTCTTCACAGGTTTGGCCTGGAGTGAATGGCCACTCTCACAGTATGCTCTAT GATCGCTATGTGGCCATCTGCCTCCCACTGCATATGAGTCAATAATGAGTCCCA GAAAGTCACTTGGGCTGTGGCAGCTGTGTGGCTAAGTGGAGGTATCTCAGGAA CATTATTCACAGCAAGTACACTCTCTATCAGATTCTGTGGGACAAATATTCA CCAGTTCTTCTGTGATATCCCGCAATTGCTCAAGCTCTCTGCTCTAATGATTACT TTGGAGTACTGGAAAGTGTCTACTTTTCATGTCTGTAATGGCCTTTGCCTGCTTGT GGGATTGCCTTCTCTATGGCCAGATATCTCTACAGTTCAGGATGCCCCCTCT GCTGAAGGCCGATCTAAGGCTCTTCCACCTGCCTGCCCATCTCTTCGTTGTTT CATTTTCTCTCAACAGGCAATTTGTGCTATCTAATTTACACACTACTACCCCAACCTCA AACTGCTTTAGACCTCATGCTCTCTATCTTTTACACACTACTACCCCAACCTCA ACCTGTTATCTATAGTCTGAGAAATGAGTCCCTTGAAAGAGCACTAAAGAAAGT TACTGCTAAGTGAAGAATTCATTAGGAAAAAATGTTTGTCTATTTTGTAGT	MTARNMTTMSGFLLMGF SDNHELQILQALLFLTYL LGSAGNFIHITTTLDPLQ SPMYFYFLKQLSTLDLSSL SVTVPPQYVASSLARSGYI SYGQCMLQIFFFTGLAWS EMATLTVMSYDRYVAIC LPLHYEVIMSPRKCTWAV AAVWLSGGISGTLFTAST LSIRFCGDKIIHQFFCDIPQ LLKLSCSNDYFGVLEVST FMSVMAFACFVGIAFSYG QIFSTVLRMPSAEGRSKV FSTCLPHLFVVSFFLSTGI CAYLKPTSDSPTALDML SIFYTLLPPTLNPVIYSLRN ESLKRALKKLLLSEEFIRK KCLFYF

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAP002826_B	29/30	TCATGGGTCGAGGAAACAGCACCTGAAGTGACTGAATCCATCTTCTGGGATTG GTGTCCAAACACGAATTCAGCATGTCCTTTTCATTGTACTTCTTCTTATCTATGTG ACCTCCCTGATAGGAAATATTGGAATGATCTTACTCATCAAGACCGATTCCAGAC TTCAAACACCCATGTACTTTTTCACAAACATTTGGCTTTTGTGATATCTGTTAT ACTTCTGCTATCACTCCCAAGATGCTCCAAAGCTTCACAGAGAAATAATTGA TAACATTTGGGGCTGTGTGATACAATCTTAGTTTATGCAACATTTGCAACCAG TGACTGTTACCTCTAGCTATTATGGCAATGGATTGTTATGTTGCCATCTGTAAG CCCCTCGCTATCCCATGATCATGTCCCAACAGTCTACATCCAACTCGTAGCTG GCTCATATATTAGGCTCAATAAATGCCTCTGTACATACAGGTTTACATTTTC ACTGTCTTCTGCAAGTCTAATAAATCAATCACTTTTCTGTGATGGTCTCCCA ATTCTTGGCCTTTCATGCTCCCAACATTGACATCAACATCTTAGATGTTGCTCT TGTGGGATTGTGACTTGATGTTCACTGAGTTGGTCACTCTTTTCTCATCTAC ATTATGGTCACCATCCTGAAGATGTTCTTCTACTGTGGGAGGAAATACTCTCT CCACATGTGCCTCCCACTGACAGCAGTAACCATTTTCTATGGGACACTCTCTTA CATGTACTTACAGCCTCAGTCTAAATATTCTCAGGAGAAATATGAAAGTAGCCTCT ATATTTTATGGCACTGTTATCCCATGTTGAATCCTTTAATCTATAGCTTGAGAA ATAAGGAAGGAAATAAGCTTTAAAGAGATGCGAG	MGRGNSTEVEFHLFGF VQHEFQHVLFIVLLIYVT SLIGNIGMILLIKTDSRLQ TPMYFFPQHLLAFVDICYT SAITPKMLQSFTEENNLIT FRGCVIQFLVYATFATSD CYLLAIMAMDCYVAICKP LRYPMIMSQTVYIQLVAG SYIIGSINASVHTGFTFSL FCKSNKINHFFCDGLPILA LSCSNIDINILDVVFVGF LMFTELVIHFSYIYIMVTIL KMSSTAGRKKSFSTCASH LTAVTIFYGTL SYMYLQP QSNNSQENMKVASIFYGT VIPMLNPLIYSLRNKEGK

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG59723-01	31/32	AGTCATGGGTCGAGGAAACAGCACTGAAGTGACTGAATGCCATCTTCTGGGATT TGGTGTC AACACGAAATTTACGCAATGTCCTTTTCATCTGTAATCTTCTTATCTATG TGACCTCCCTGATAGGAAATATTGGAATGATCTTACTCATCAAGACCGATTCCAG ACTTCAAAACACCCATGTACTTTTCCACAACATTTGGCTTTTGTGATATCTGTT ATACTTCTGCTATCACTCCCAAGATGCTCCAAAGCTTCACAGAAGAAATAATTT GATAACATTTCCGGGCTGTGTGATACAATCTTATGTTTATGCAACATTTGCAACC AGTGACTGTTACCTCCTAGCTATTATGGCAATGATTGTTATGTTGCCATCTGTA AGCCCCCTCGCTATCCCATGATCATGTCCCAACAGTCTACATCCAACTCGTAGC TGGCTCATATATTATAGGCTCAATAAATGCCTCTGTACATACAGGTTTACATTT TCACTGTCTTCTGCAAGTCTAATAAATCAATCACTTTTCTGTGATGGTCTCCC AATCTTGCCCTTTCATGCTCCCAACATTGACATCAACATCTTCTAGATGTTGTCT TTGTGGGATTGACTTGATGTTCACTGAGTTGGTCATCATCTTTTCCCTACATCTAC ATTATGGTCACCATCCTGAAGATGTCTTCTACTGTGGGAGGAAATAATCCTTCT CCACATGTGCTCCCACTGACAGCAGTAACCAATTTCTATGGGACACTCTCTTA CATGTACTTACAGCCTCAGTCTAATAATTCTCAGGAGAAATAGAAAGTAGCCTCT ATATTTTATGGCACTGTTATTTCCATGTTGAAATCCTTTAATCTATAGCTTGAGAA ATAAGGAAGGAAATAAGCTTTAAAGAGATGCGAG	MGRGNSTEVTEFHLLGFG VQHEFQHVLFVIVLLIYVT SLIGNIGMILLIKTDSRLQ TPMYFFPQHLLAFVDICYT SAITPKMLQSFTEENNLIIT FRGCVIQFLVYATFATSD CYLLAIMAMDCYVAICKP LRYPMIMSQTVYIQLVAG SYIIGSINASVHTGFTFSL FCKSNKINHFFCDGLPILA LSCSNIDINIILDVVFGFD LMFTELVIIFSYYIMVTIL KMSSTAGRKKSFSTCASH LTAVTIFYGTL SYMYLQP QSNN SQENMKVASIFYGT VISMLNPLIYSLRNKEGK

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GM524k20_C	33/34	<p>ATGGGCCAACACAACTCTAACAGTGCCTAACTGAATTCATTCGTGATGGAACTCACA</p> <p>AGCGGCCCTGAGCTGCAGATTCCCTCTTTTGGAGCTCTTCCTCGTCATCTACCTAA</p> <p>TACAGTGGTGGCAACCTAACTATGATCATTTTGACCAAACTGGACTCCCACTT</p> <p>ACATACACCTATGTACTTTTCTATCAGACATTTGGCTTCTGTTGATCTTGGTAATT</p> <p>CTACTGTCAATTTGTCCTCAAGGTGCTGCACAGCTGGCAATTTTGTGTGGATCGAAATACTAT</p> <p>TTCTATTATGCAATGCTGCACAGCTGGCAATTTTCTTATGTTCAATTATCAGTG</p> <p>AATTTTTCATCCTGTGAGCCATGGCCTATGACCGCTATGTGGCCATTTGTAAACCC</p> <p>TCTGCTCTATTATGTTATTATGCTCAGCGACTGTGTCATGTACTGTGGGCATT</p> <p>CAATATCTACAGCACATTTTCAGGCTCTGATGTTCACTATTAAAGATTTTACAT</p> <p>TGACCTTCTGTGGCTCTAAATGTCATCAGTCATTTTACTGTGATGATGTTCCCTTG</p> <p>CTACCTATGCTTTGCTCAAATGCACAGGAAATAGAAATGTTGAGCATACTATTTT</p> <p>CTGTATTTAAATTTGATCTCCTCTCTTCTGATAGTCTTAGTGCTCTACATGTTGATT</p> <p>TTGTTAGCTATATGTCAAATGCATTTCTGCAGAGGCGAGGAAAAGGCTTTCTCC</p> <p>ACATGTGTTCCCATTTGACAGTGGTGGTTGTTCTATGGGTCTCTACTCTTCA</p> <p>TGTACATGCAGCCCAATCCCACTCACTTCTTTGATACACTGATAAAATGGCTTCTGT</p> <p>GTTTACACTTTAGTAAATCCCATGCTTAACCTTTGATTTACAGCTTAAGAAAC</p> <p>GAAGAGGTGAAAAATGCCTTCTATAAGCTCTTTGAGAATTGAT</p>	<p>MGQHNLTVLTFILMELT</p> <p>RRPELQIPLFGVFLVIYLI</p> <p>VVGNLTMIILTKLDSHLH</p> <p>TPMYFSIRHLASVDLGNS</p> <p>TVICPKVLANFVVDRNTI</p> <p>SYACAAQLAFFLFIISE</p> <p>FFILSAMAYDRYVAICNP</p> <p>LLYYVIMSQRLCHVLVGI</p> <p>QYLYSTFQALMFTIKIFTL</p> <p>TFCGSNVISHFYCDDVPL</p> <p>LPMLCSNAQEIELLSILFS</p> <p>VFNLISSFLIVLSYMLILL</p> <p>AICQMHSAGEGRKKAFTC</p> <p>GSHLTIVVVVFYGSLLFM</p> <p>YMQPNSTHFFDITDKMAS</p> <p>VFYTLVIPMLNPLIYSLRN</p> <p>EEVKNAFYKLFEN</p>

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG55944-01	35/36	ATGGGCCAACACAACTAACAGTGTCTAACTGAATTCATCTCTGATGGAACTCACA AGGGGGCTGAGCTGCAGATTCCCTTTTGGAGCTTCTCCTGTCATCTACCTAA TCACAGTGGTGGCAACCTAACTATGATCATTTTGACCAAACTGGACTCCCACTT ACATACACCTATGTACTTTTCTATCAGACATTTGGCTTCTGTGATCTTGGTAATT CTACTGTCAATTTGTCCCAAGGTGCTGCACAGCTGGCATTCTCCTTATGTTCAATTATCAGTG TTCCCTATTATGCATGTGTCACAGCTGGCCTATGACCGCTATGTGGCCATTGTAAACCC AATTTTTCATCCTGTGAGCCATGGCTATGCTCAGGACTGTGTCATGTAAGATTTTACAT TCTGCTCTATTATGTTATTATGCTCAGGCTGTGTTCACTATTAAAGATTTTACAT CAATATCTCTACAGCACATTTTCAGGCTGTGTTCACTATTAAAGATTTTACAT TGACCTTCTGTGGCTCTAATGTCATCAGTCAATTTTACTGTGATGATGTTCCCTTG CTACCTATGCTTGGCTCAAATGCACAGGAAATAGAAATGTTGAGCATACTATTT CTGTATTTAAATTTGATCTCCTCCTTTCTGATAGTCTTAGTGCTCCTACATGTTGATT TTGTTAGCTATATGTCAAATGCATTTCTGCAGAGGGCAGGAAAAGGCTTCTCTCC ACATGTGGTTCCCAATTTGACAGTGGTGTGTTGTTCTATGGGCTCTACTCTTCA TGTACATGCAGCCCAATTCCCACTCACTTCTTTGATACACTGATAAAATGGCTTCTGT GTTTTACACTTTAGTAAATCCCATGCTTAACCCCTTTGATTTACAGCTTAAGAAAC GAAGAGGTGAAAAATGCCTTCTATAAGCTCTTTTGAGAATTGAT	MGQHNLTVLTFELMELT RRPELQIPLFGVFLVIYLT VVGNLTMIILTKLDLH TPMYFSIRHLASVDLGN TVICPKVLANFVVDRNTI SYVACAAQLAFFLMFIIE FFILSAMAYDRYVAICNP LLYVYVIMSQRCHLVVGI QYLYSTFQALMFTIKIFTL TFCGSNVISHFYCDDVPL LPMLCSNAQEIELLSILFS VFNLISFLIVLSYMLILL AICQMHSAEGRKKAFSTC GSHLTVVVVFYGPLLFM YMQPNSTHFFDTDKMAS VFYTLVIPMLNPLIYSLRN EEVKNAFYKLFEN

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL359352_B	37/38	AATTTAACTGTTAAATACTAATATGTGGATCAATAATCAGAGCTCAGTAGATGAC TTCAATCTATTGGGATTTCTGACCGGCTTGGCTGGAGACACCTCTCTTTGTAA TTTTCTGTGGCTACATCTTTGGCTTATTGTGTAATATCTCCATTATCTCAGTT TCCCGCTAGACCCCACTTGACAGCCCATGTACTTTTGTCTCCAACCTTTC TCTCTGGACCTCTGCTATACTACGAGCACTGTCCCTCAGATGTTGGTCAACCTT AGAGGCTGAAAGACCATCAGCTATGTTGGCTGTGTGGCCAGCTCTATATT TCTTGGCTTTGGGCTCAACTGAATGTATCTCTGGCCATCATGGCTTTGACC GTTTTGCTGCCATTTGCAGACCCCTTCACTATCTATCATCATGAACCAAGAACG ATGCATTATATGGCCACAGGACCTGGATTAGCGGATTGCAAACTCTCTTGTG CAGTCCACCTCACTGTGTAGCCCCAGGTGTGGACAGAGGTAATAGACCAT TTCTTCTGTGAAGTCCAGCCCTTTTGAACACTAGCTTGCACTGACACAAAGTGA ATGAAGCTGAGCTTAATGTTCTTGGAGCTTTGCTGCTCTTGGTGCCTCTCAGCCT CATCTGGTACCTATGTGTTTCATTGCTCAAGCACTGAACTCCGTTCTGCT GAGAGTCGCAGGAAGGCAATTTAAATACCTGTGCTTCACTGCTGTGGTCTCCCT TCTTCTACTTCACAGCTATCAGTATGTAATGTTTCAGCTCCCTCAAGCTACTCTCAT GAAAGGGCAAGATCATGGCTCTGTTCTATGGCATGTGCACACCTACCTCAACCT CATTCTATACACTTTGAGGAATAAGGATGTTAAGGCTGCCCTGAGGAGGCAC TAACAAAGGAGTTTGGGTCAAGGCAAGGCAATAGCTAGAGAAAGATCAAAAGA AGCAAGAATTAAACAGATTGCTTCTCAAAGACAATTCTGGACTTGGAAATTCATG AGGAATCAAATGCCACAGAGATCACAAAGA	MWNNQSSVDDFILLGFS DRPWLETPLFVIFLVAYIF ALFGNISHILVSRDPQLDS PMYFFVSNLSLLDLCTTT STVPQMLVNLRGPEKTIS YGGCVAQLYIFLALGSTE CILLAIMAFDRFAAICRPL HYPIIMNQKRCIHMAITGT WISGFANSLVQSTLTVA PRCGRVIDHFFCEVPAL LKLACTDTSVNEAELNVL GALLLVPLSLILGTYYFI AQAVLKLRSASRRKAFN TCASHLLVVSIFYFTAIS MYVQPPSSYSHERGKIMA LFYGVITPTLNPFIYTLRN KDVKAALRRALTKFEWV KARQ

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL365336_E	39/40	AATTTAACTGTTAAATACTAATAATGTGGATCAATAATCAGAGCTCAGTAGATGAC TTCATCTTATTGGGATTTCTGACCGCCTTGGCTGGAGACACCTCTCTTTGTAA TTTTCTGCTGGCTACATCTTTGGCCTTATTTGGTAATAATCTCCATTATCCTAGTT TCCCGCTAGACCCCAAGCTTGACAGCCCCCATGTACTTTTGTCTCCAAACCTTTC TCTTCTGGACCTCTGCTATACAGAGCACTGTCCCTCAGATGTTGGTCAACCTT AGAGGCTCTGAAAGACCATCAGCTATGTTGGCTGTGTGGCCCATGAGCTCTATATT TTCTTGGCTTGGGCTCAACTGAATGATCTTCTGGCCATCATGGCCTTTGACC GTTTTGTGCTGCCATTGACAGACCCCTTCACTATCTATCATCATGAACCAAGAAACG ATGCATTCAATATGGCCACAGGACCTGGATTAGCGGATTGCAAACTCTCTTGTG CAGTCCACCTCACTGTGGTAGCCCCCAGGTGTGGACAGAGGTAATAGACCAT TTCTTCTGTGAAGTCCAGCCCTTTTGAACCTAGCTTGCACTGACACAAAGTGTA ATGAAGCTGAGCTTAATGTCTTGGAGCTTTGCTGCTCTTGGTGCTCTCAGCCT CATCTGGTACCTATGTGTTCAATGCTCAAGCAGTACTGAACTCCGTTCTGCT GAGAGTCGCAGGAAGGCAATTAATACTGTGCTTCACTCTGCTGGTGCTCTCC TCTTCTACTTCACAGCTATCAGTATGTATGTTTCAGCCTCCCTCAAGCTACTCTCAT GAAAGGGGCAAGATCATGGCTCTGTTCTATGGCAATTGTACACCTACCTCAACCT CATTCATCTACACTTTGAGGAATAAGGATGTTAAGGCTGCCCTGAGGAGGGCAC TAACAAAGGAGTTTGGGTCAAGGCAAGGCAATAGCTAGAGAAAGATCAAAGA AGCAAGAATTAAACAGATTGCTTCTCAAAGACAAATTCTGGACTTGGAAATTCATG AGGAATCAAATGCCACAGAGATCAACAAGA	MWNNQSSVDDFILLGFS DRPWLETPLFVIFLVAYIF ALFGNISILVSRDPQLDS PMYFFVSNLSLLDLCYTT STVPQMLVNLRGPEKTIS YGGCVAQLYIFLALGSTE CILLAIMAFDRFAAICRPL HYPIIMNQKRCIHMATGT WISGFANSLVQSTLTVA PRCGQRVIDHFFOEVPAL LKLACTDTSVNEAELNVL GALLLVPLSLILGTYVFI AQAVLKLSAESRRKAFN TCASHLLVVSIFYTAIS MYVQPPSSYSHERGKIMA LFYGIVTPTLNPFIYTLRN KDVKAAALRRALTKFWV KARQ

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068902_B	41/42	AACATGACTGGAAACAACCAACCTTTGATATCAAAAGTTCCTCTCTGCGGTCTGC CCATCTTGTCAGAGTATCATTTCCCTGTTCTATGCCCTGTTCTCTGCCATGTACCTC ACCACTATCCTGGGAAACCTGCTAATCATTTGCCCTTGTTCGACTGGATTCCCATC TCCACACACCAATGTACTTGTTCAGCAACTTGTCCCTTCTCTGATCTCTGCTTT TCCTCTGTCACAATCCCCAAATTGCTTCAGAACATGCAGAGCCCAAGTACCATCTA TATCTTATGTGGCTGCTGACACAGCTGACTTCTTATGGTTTGTGGAGATAT GGAAAGCTTTCTTGTGGTCATGGCCTATGATCGTTATGTGGCCATCTGCTTT CCTTTGCATTACACCAAGCATCATGATGATCAAGTTCTGTACTTCACCTAGTGTAC TACTGTGGATGCTGACAAACATCTAATGCCTTGATGCACACCTTGTCTCATGGCTAG ATTGTCTTTTGTGAGAAAGATGTGATTCTCCGCTTTTCTGTGACATTTCTGCTC TTCTGAAGTTGCTGCTCAGACACATTTTGTAAATGAGTTGATGATATTTATCAT GGGAGTATCATTAATTAATTCATTCCTACTCATAGTTATGTCTCTATGTAAGG ATTTTCTTCTCCATTCTCAAGTCCCATCTACACAGGGCATCCACAAGTCTTTT CTACATGTGGATCCCATCTGTCTGTGGTGTCTGTCTGTATGGAACAAATTATTGG TCTATACTTATGCCCATCAAGTAAATAATTCCACTGTAAAGAGAGTGGCATGGCT ATGATGTACACAGTGGTGACTCCTATGTGTAACCCCTTTCATCTACAGTCTGAGGA ACAGAGACATGAAGAGAGGCCCTAATAAGAGTTATCTGCAGTAAGAAAATCTCTC TGTAATGGAA	MTGNNQTLISKFLLGLPI LSEYHFLFYALFLAMYL TILGNLLIHALVRLD TPMYLFLSNLSFSDLCFSS VTIPKLLQNMOSQVPSISY VGCLTQLYFFMVFGDME SFLLVVMAYDRYVAICFP LHYTSIMSTKFCSTSLVLL WMLTTSNALMHTLLMAR LSFCEKNVILRFFCDISAL LKLSCSDTFVNELMIFMG GHIIPFLLIVMSYVRIFFSI LKVPSTQGIHKVFSTCGS HLSVVSIFYGTIIGLYLCP SSNNSTVKESAMAMMYT VVTPMLNPFYISLRNDRM KRALIRVICKKISL

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAL358874_A	43/44	CTTTCATCATCCACCGATGCCCAATTCAACCACCGTGATGGAATTTCTCCTCATGA GGTTTCTGTGATGTGGACACTACAGATTTTACATTTCTGCATCCTCTTTATGTG TATTTGGTAACTCTAATGGGAAACATCCTCATTTGTGACCGTCACACCTGTGACA GCAGCCTTCACATGCCCATGTACTTCTTCTCAGGAATCTGTCTATCTTGGATGC CTGCTACATTTCTGTACAGTCCCTACCTCATGTGTCAATTCCTACTGGACAGC ACCACCATTTCTAAGCGGGATGTAGCTCAGGTCTTCTCGTGGTTTTTTTGT TATATGTGGAGCTTCTGTTTCTACCATTTATGGCTCATGACCGCTATGTGGCTGT CTGCCAGCCACTTCACTACCTGTGATCGTGAACCTCTCGAATCTGCATCCAGATG AACTGGCCTCCCTACTCAGTGGTCTGTATGCAGGCAATGCACACTGGCAGCA CATTCCAGTCCCTTCTGTGGTCCCAACGTTATTCATCAATTTCTTCTGTGACATC CCTCTCTGTGAAGCTCTCTTGTCTGTGACACCTTCAGCAATGAGGTCAATGTTG TTGTCTCTGTCTGGGGTGAAGTGGCGGCTGTTTCACTTTATCATCAGGTCTTA CATTACACAICTTTTCGACCGTGTCTGGGTTTCCAAAGAGAGCAGACAGAAACAA GGCTTTTCCACCTGCAATCCCTCACAATCCTGGTGTGTGCTCTTCTCAGTTTCAT GCTCTTCTGTGTACCTCAGGCCACCTCGGATACCTGCAGCCACCCAGGATCTGAT CCTTCTGGTTTTTATTCATAAATGCCCTCCCTCTTTAAACCTATTATTACAGTC TTAGAAATAAGCAAAATAAAGGTGGCCATCAAGAAAATCATGAAGAGAATTTTT ATTCAGAAAAATGTGTAGAAACCCGAGAGGCTCACCCCTAGGCT	MPNSTTVMFLLMRFS VWTQLHLSAFFMLYL TLMGNILIVTVTTCDSSLH MPMYFFLRNLSILDACYIS VTVPTSCVNSLLDSTTISK AGCVAQVFLVVFVYVE LLFLTIMAHDYVAVCQP LHYPVIVNSRICIQTMLAS LLSGLVYAGMHTGSTFQL PFCRSNVHQFFCDIPSL KLSCTDFTSNEVMIVVSA LGVGGGCFIIRSYIHFS TVLGFPRGADRTKAFSTC IPHILVVSFLSSCSSVYL RPPAIPAATQDLILSGFYSI MPPLFNPIIYSLRNKQIKV AIKKIMKRIFYSENV

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMba245d2_B	45/46	CTTCATCATCCACCGATGCCCAATTCAACACCGTGATGGAAATTTCTCCTCATGA GGTTTCTGATGTGTGGACACTACAGATTTTACATTTCTGCATCCTCTTTATGTG TATTTGGTAACTCTAATGGGAAACATCCTCATTTGTACCGTCACCACTGTGACA GCAGCCTTCACATGCCCATGTACTTCTTCTCAGGAATCTGTCTATCTTGGATGC CTGCTACATTTCTGTTACAGTCCCTACCTCATGTGTCAATTCCTACTGGACAGC ACCACCATTTCTAAGCGGGATGTAGCTCAGGTCTTCTCTCGTGGTTTTTTTG TATATGTGGAGCTTCTGTTCTCACCATTATGGCTCATGACCGCTATGTGGCTGT CTGCCAGCCACTTCACTACCTGTGATCGTGAATCTCGAATCTGCATCCAGATG ACACTGGCCTCCCTACTCAGTGGTCTTGTCTATGCAGGCATGCACATGGCAGCA CATTCCAGTGCCTTCTGTGGTCCCAAGTTATTCATCAATTCCTCTGTGACATC CCCTCTCTGTGAAGCTCTTGTCTGTGACACCTTCAGCAATGAGGTCAATGATG TTGTCTCTGTCTGGGGTAGGTGGCGGCTGTTTCATCTTTATCATCAGGTCTTA CATTACACATCTTTTCGACCGTGTCTCGGGTTTCCAAAGAGAGCAGACAGAAACA GGCCTTTTCCACCTGCATCCCTCACAATCCTGGTGTGTGCTCTTCTCAGTTTCAT GCTCTTCTGTGTACCTCAGGCCACCTCGGATACCTGCAGCCACCCAGGATCTGAT CCTTCTGTGTTTTTATTCATCAATGCTTCCCTCTTTAAACCCTATTATTACAGTC TTAGAAATAAGCAAAATAAAGGTGGCCATCAAGAAATCATGAAGAGAATTTTTT ATTCAGAAAAATGTGTAAAGAAACCCGAGAGGCTCACCCCTAGGCT	MPNSTTVMEFLLMRFS VWTLQILHSASFFMLYLV TLMGNILIVTVTTCDSLLH MPMYFFLRNLSILDACYIS VTVPTSCVNSLLDSTTISK AGCVAQVFLVVFVYVE LLFLTIMAHDYVAVCQP LHYPVIVNSRICIQTMLAS LLSGLVYAGMHTGSTFQL PFCSRNVHQFFCDIPSLL KLSCSDTFSNEVMIVVSA LGVGGGCFIIRSYIHFS TVLGFPRGADRTKAFSTC IPHILVVSFLSSCSSVYL RPPAIPAATQDLJLSGFYSI MPPLFNPIIYSLRNKQIKV AIKKIMKRIFYSENV

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068910_C	47/48	AATGGTATTAGAAAAATTCTCTTCAGTGAAAGAAATTTATCCTGCTGGGCTTGACA CAGCAACAGAGCTCCAAATGCCTCTCTTTTCTCTGTTCTTGGGAATCTACATTG TATCCATGGTGGGGAACCTGGCTTGACTGTTCTGATTGTTTGAATCCTCACCT GCACAACCCCATGTACTACTTTCTCTTCAACCTTTCCCTTCACAGATCTCTGCTACT CCACTGTCATAACCCCAAGAAATGCTGGTGGGTTTTGTGAAGCAGAACACCATCTCT TCATGCTGAGTGTCATGACTCAACACTTTTCTTTGCTTCTTTGTTATTGATGAAT GCTACATTTTGACAGCAGTGGCCTATGACAGATATGCTGCCATCTGTAAAGCCTCT ACTTTACCAAGTTACCATGTCTCATCAGGTTTGCTGCTGATGACAGTTGGGGTG TATGTGATGGGATTTTGGGAAGCCATTGCACACACTGGTAGTAGTGGTAAGCCTG ACCTTCTGTGATGGCAACATTATTAATCACTATGCATGTGACATACTTCCTCTCC TCAAACTCTCCTGCACAGCACCACCATCAATGAGTTGGTGGTTTTCATTGTTGT GGGTGTCAATGTCAATAGTTCCCAACCTGACAACTCTTATTTCTTACACCTTGATC CTTTCCAAACATCCTCAGCATCCATCTGTCAGAAAGTAGGTCAAAAGCCTTCAGTA CCTGTGGCTCCCATGTGATTGCTGTTTCACTTTCTTTGGAGCTGCAGCCTTCATG TATCTTAAAGCCTTCTAGTGTCATCTGAGGATGATGATAAAGTATCTACTATCTTT ATACCATTTGTGGGCCCAATGCTGAATCCTTTTCATCTACAGTCTAAGGAATAAGGA TGTCTACCTTGCACTTAGAAAAAATTTGTATGAAAAGGAGTTTTTACCTAA	MVLESSSVKEFILLGLT QQPELQMPLFFFLGIYIV SMVGNLGLTVLIVLNPHL HNPMYYFLENLSFTDLCY STVITPRMLVGFVKQNTIS HAECMTQHFFCFVVIDE CYILTA VAYDRYAAICKP LLYQV'TMSHQVCLLMTV GVVYVMGFLEAIAHTGSM VSLTFCDGNINHYACDIL PLLKLSCTSTTNELVVF VVGVNVIPTLTIFISYTLI LSNILSIHSAEGRSKAFST CGSHVIAVSLFFGAAAFM YLKPSSASEDDDKVSTIF YTVIGPMLNPFYSLRNK DVYLALRKTLMKRSFT

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068902_A	49/50	AATGATAATAATAATCAGACTGCCATCCCTCAGTTCATCTCTGGGCGCTGCC ATCTCCAGAGCAGCAGCAAAATGTTCTATGCCCTGTTCTGGCCATGTACCTCA CCACTGCTCTGGGAAACCTCATCATCATCATCTCATCTCGACTGGACTCCCATCT CCACACACCCATGTACTTGTCTCTCAGCAACTTGTCTCTCTGATCTCTGCTTTT CCTCTGCACAATGCCCAAATGCTGCAGAACATTCAGAGCCAGGACCCATCCAT CTCCTATGCCGGTGCTGACACAAATGTAATTTTCATGGTTTTCGAAACACA GAGAAATGTTCTTCTGTGTCATGGCCTATGACCGCTATGTGGCCATCTGCTTCC CTCTTCATTACACCGCATCATGAGCCCTAAGCTCTGTGTCTCTGCTGGTGCT CACCTGGGTATTTACCGTCTGTATTCATGTTACACACCCCTACTCTTGGCAAGA TTGTCAATCTGTGAGGACAAATGTAATCACCCACTTTTCTGTGACATATCTGCC TGCTCAAGTTGGCCTGCTGACACTTATATTAATGAACATAATGATATTTATCTT GGGAACACTTGATCTGTGGTCCCATCTTACTCATTTGTGTTTCTCTATGTACAA ATTGTCTGCTCCATTCTAAAGTTTTCAACTAAACAGGGCATAGCCAAAGGTCTTT CCACCTGTGGCTCCCACTGTCTGTGTCTCACTGTTCTATGGGACAAATTATTGG TGCTACTTATGCCCATCAGCTAATAACTCTACTGTAAAGGAGATTGTCATGGCT CTGATGTACACAGTGGTGACTCCCATGCTGTAATCCATTCTACAGTCTGAGAA ACAGAGATATAAAAGAGGCCCTGATCAGAGTCTCTATGTAAGAAGCAAAATCCCT TATAAT	MINNQTAIPQFILLGLPIL PEQQMFYALFLAMYL TVLGNLIHILRLDSHLHT PMYLFSLNLSFSDLCFSSV TMPKLLQNIQSQDPSISYA GCLTQMYFFMVFANTEN VLLVVMAYDRYVAICFPL HYTSIMSPKLCVSLVVLT WVFTVLYSMLHTLLAR LSFCEDNVITHFFCDISAL LKLACSDTYINELMIFILG TLDTVVPFLLIVSVYVQIV CSILKFSTKQGIKVFSTC GSHLSVVSIFYGTIGVYL CPSANNSTVKEIVMALM YTVVTPMLNPFYSLRNR DIKEALIRVLCKKQIPL

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC036111_B	51/52	ACATGGGCAAGGAAACTGCACCACCTGTGGCTGAGTTCATCTCCTTGGACTATC AGATGTCCCTGAGTTGAGAGTCTGCCCTCTTCTGTCTTCTTCTCATCTATGGA GTCACGTTGTTAGCCAACTCTGGGCATGACTGCACCTGATTCAGGTCAGCTCTCGGC TCCACACCCCGTGACTTTTCCCTCAGCCACTTGTCTTGTAGATTCTCTGCTAC TCCTCAATAATTGTGCCAAAGATGTTGGCTAATATCTTTAAACAAGGACAAAGCCA TCTCCTTCTAGGGTGATGGTGCAATTCTACTTGTTTTGACACATGTGGAGTCAC TGAGGCTTCTCCTGCTGCCGTGATGGCCTATGACCGCTTGTGGCCATCTGTAAC CCCTGCTGTACATGGTGACCATGTCTCAAAAGCTGCGTGTGGAGCTGACCTCTT GCTGCTACTTCTGTGGACGGTGTCTCTGATTCACTCGTCTTACCTCTTAG GATCCTTCTATAGATCTAATGTGATTAAACCACTTCTTCTGTGATCTACCCCTC TCCTAAGCTTGTGCTGTGATGTCATGTGAATGAGACACTGCTGTCTCTGGT GGCCACTTTGAATGAGAGTGTACCATCATGATCATCTCACCTCCTACCTGCTA ATTCTCACCACTATCCTGAAGATACACTCTGCAGAGAGCAGGACAAAGCTTTCT CCACCTGTGCCTCCCACTCACAGCATCACTGTCTCCCATGGAACAAATCCTTTA CAITTTATTGCAGGCGGAGTTCAGGCAACAGTGGAGATGTTGACAAAGTGGCCAC CGTGTCTACACAGTTGTGATTCCCATGTGTAACCCCTGTATCTACAGCCTGAGA AATAAGGATGTGAACAAAGCTCTCAGAAAAGTGTGGGCTCCAAAATTCACTCC TAGGGAAGATTTTATTACAGAAATTCAGGATCCCCAA	MGKENCITVAEILLGLS DVPELRVCLFLLFLIYGV TLLANLGMTALIQVSSRL HTPVYFFLSHLSFVDFCYS SIIVPKMLANIFNKKDKAIS FLGCMVQFYLFCTCGVTE VFLAVMAYDRFVAICNP LLYMTVMSQKLRVELTS CCYFCGTVCSLIHSSLALR ILFYRSNVINHFFCDLPL LSLACSDVTVNETLLFLV ATLNE SVTIMILTSYLLIL TTILKIHSAESRHKAFSTC ASHLTAITVSHGTILYIYC RPSSGNSGDVDKVATVF YTVVIPMLNPLIYSLRNK DVNKALRKVMGSKIHS

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC027184_A	53/54	ATGCCATGAACAGATCAGCAGCACATGTAACCTGAAATTTGTTCTCTTGGGATTTC TGGTTCCTGGAAGATACAGATTTTCCTCTCGTGTGTTGTTTGGTGTTTATGTCCT TGACATTTGTTGGAAATGGAGCCATCATCTGTGCAGTAAGATGTGACTCACGTC TACATACCCCATGTACTTCTCTCTGGGAAATTTGCTTCTTGAATCTTGTA TGTTCCTCCACTATTCCTAACATACTAGCCAAACATTCGTCTAAGACCAAGGCC ATCTCATTTTCAGGGTCTTCTCTGAGTTCTATTTCTTCTTTTCACTAGGTACAAC TGAATGCTCTTCTCTGGCAGTAATGGCTTATGATAGGTACCTGGCCATTGCGCG CCATTACATTACCCATCCATGACTAGGAGGCTGTGTGCTATCTGCTATCTCT CATGCTGGCTCATTTGGATTTCTTGGGTACCCATCCCTATCTTCTCCATTTCCTCAG CTTCCCTCTGTGGTTCTAATATCATTTGATCATCTTCTCTGTGACATGGACCCATT GATGGCTTTGTCTGTGCCCCAGCTCCTATTACTGAATTTATTTTATGCCCCAA GTTCCTTTGTCTCTTTTCACTATTGCATACATTTCTCGGTCTCTATTTTGTGTTG CTCAGGCTGTTTTTCAGGTTCTTCTGTCAGCTGGCCGACGAAAGCCCTTCTCTA CCTGTGGTTCCCATTTAGTTGTGGTATCACTCTTCTATGGTACAGTAATGGTAAT GTATGTGAGTCTACATAATGGCAATCCAAATTTTGATGCAGAAGATCCTTACACTT GTATACTCTGTAATGACTCCTCTCTTAATCCTCTGATTTATAGCCTTCGTAAACAA GGACATGAAACTTGCTCTGAGAAATGTTCTGTAGGAATGAGAATTGTCAAAA TATGTAA	MNRSAAHVTEFVLLGFPG SWKIQIFLVFLVFYVLT LLGNAGIICAVRCDRLH TPMYFLLGNFAFLEIYV SSTIPNILANILSKTKAISF SGCFLQFYFFFSLSGTTECL FLAVMAYDRYLAICRPLH YPTIMTRRLCCILVSSCW LIGFLGYPIPIFSISQLPFCG SNIIDHFLCDMDPLMALS CAPAPITEFIFYAQSSFVLF FTIAYILRSYILLRAVFPQ VPSAAGRRKAFSTCGSHL VVVSIFYGTVMVMYVSP TYGIPILMQKILTLYSV MTPLFNPLIYSLRNKDMK LALRNVLLGMRIKKNM

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC025942_A	55/56	GACATGGAACAGGATAATACAAACATTGCTGACAGAGTTTGTCTCACAGGACCTT ACATATCAGCCAGAGTGGAATAATGCCCTGTCTCTGGTGTCTCTGGTGATCTATC TCATCACTATTGTGTGGAACCTTGGTCTGATTGCTCTTATCTGGAATGACCCACA ACTTCACATCCCCATGTACTTTTCTTGGGAGTTTGGCCTTTGTGATGCTTGGGA TATCTTCCACAGTAACCTCCCAAAATGTTGGTTAATTTCTTGGCCAAAAACAGGAT GATATCTGTCTGAATGCATGATTCAAATTTTCTTGGCCTTGGCCTTGGTGAACCTA CAGAATGTTTCTCTTGGCAACAATGGCATATGATCGCTATGAGCCATATGCAA ACCTTACTATATCCAGTGATTATGAACAATTCACATATGCATACGGCTGTTAGCC TTCTCAATTTTAGTGGCTTCTCCCATGCCCTAATTCATGAAGTCTTATATTCAG ATTAACTTCTGCAATCTAACATAATACATCATTTTACTGTGATATTATACCAC TGTTTATGATTTCTGTACTGACCTTCTATTAATTTCTAATGGTTTATTTTG TCTGGCTCAATTCAGGTATTCACCAATTTGTGACAGTCTTAATCTTACACATTTG CTCTTTTACAAATCCTAAAAGAAGTCTGTAGAGCGTAAGGAAAGCCTTTTC CACCTGTGGAGCCCATCTCTTATCTGTCTCTTTATATTATGGCCACTTATCTTCA TGTAATTTGGCCCTGCATCTCCCAAGCAGATGACCAAGATATGATAGACTCTGT CTTTTATACAATCATAAATTCCTTTGTCTAAATCCCATTAATCTACAGTCTGAGAAAT AAACAAAGTAATAGATTTCATTCACAAAAATGGTAAAGAAATGTTTAGATTTCAT TA	MEQDNTLLTEFVLTLGLT YQPEWKMPFLVFLVIYL ITIVWNLGLIALIWNDPQL HIPMYFFLGLSLAFVDAWI SSTVTPKMLVNFLAKNR MISLSECMIQFFSFAGGT TECFLLATMAYDRYVAIC KPLLYPVIMNNSLCIRLLA FSFLGGFLHALIHEVLIFR LTFCNSNIHHFYCDIPLF MISCTDPSINFMLMVFILSG SIQVFTIVTVLNSYTFALF TILKKKSVRGVRKAFSTC GAHLLSVSLYYGPLIFMY LRPASQADDQDMDSVF YTHIPLLNPIIYSLRNKQVI DSFTKMVKRNV

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069559_H	57/58	AATGGGTTTTGAAAAATGGCTCTTCAGTGACTGAATTCATTCGTGGGATTAAACC AAGGAGTCCGATCTCCAGTGCCTCTTCATCCTGTTCTAATGATGATGTGG TCACGTGCTGGGAAATCAGGGTTTGATTAGCTTAATTGGACTGAACTCTCATCT CCACACTCCAATGTAATTTTCCCTCTTAACCTTGCTCCTTGTGACCTCTGTGACT CTTCTGTTTTCACACCCAAATGCTGGAGAGCTTTATATCAGAGAAGAATACTAT TTCCTACAGAGGATGCATGGCACAGCTTTCTTTCTGTTTCTCCATCTCTG AGTGTACATTTTGACCTCAATGGCCTATGATCGCTATGTGGCCATTGTAAACCC ACTCTGTATAATATTGTCATGTCCTAAACAATGTTTGATCCTTATGTTAGTT CATAATGATGGCATTTTCTGGTGCCATGGCTCACCGGATGCATGCTGAGACT GACCTTCTGTGATGCTAACACCATCAATCACTACTTCTGTGACATCCTCCCTTG CTTCAGCTCTCTGCACCAACCTATGTCAATGAACCTGGAGGTATTGTTGTTG TGGGCATCAACATCAATTGTGCCCCACTATCACCATCTTTATCTCTTATGGTTTATC ATCGCAAGTATTTTCGTATCAGCTCCAGGAGGACAGGTCCAAAGCCTTCAGC ACCTGCAGCTCCACATAAATTGCAGTTTCTCTGTTCTTTGGATCAGGTGCATTTA TGTAATCTCAAAACCATCTTCTGCTGAGTCAATGAATGAAGGCAAAATCTCCTCTAT CTTTTATACCAATACAGTTCTCTGCTGAATCCCTTAATCTACAGCTTGAGGAAC AAAGATGTTAAAGATGCCTTGATAAAGACCCTGAGTAAGAGAAAGCGTTAAAAAT GAACGA	MGFENGSSVTEFILVGLT KESDLQCPLFILFLMMYV VTVLGNQGLISLIGLNSHL HTPMYFFLFNLSFVDLWY SSVFTPKMLESFISEKNTIS YRGCMAQLFFFCFFSISEC YILTSMAYDRYVAICNPL LYNIVMSPKQCLILMFSS YMMAFSGAMAHTGCML RLTFCDANTINHYFCDILP LLQLSCTSTYVNELEVFV VVGNIIVPTITIFISYGFILA SIFRISKEDRSKAFSTCSS HIIAVSLFFGSGAFMYLKP SSAESMNEGKISSIFYTNT VPLLNPLYSLRNKDVKD ALIKTLSKRKR

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069559_D	59/60	AAAAAAAAAATGGCCTCTGCAATGTGTCTTTTGGTGACTGAATTCATTCCTGGTAG GTTTAACAAAACCCAGCCTGATCTTCAATAACCTCTGTCTTTGTGTTCTCTAAATAAT GTATATTGTTACTGTCATAGGAAAATTGTGTTTGATAAATCTTATTGTACTAAAT TCACACCTTCACACCCCTATGTACTTTTTCCTCTTTAACTTGTCCTTCATAGACCT CTGCTACTCTACTGTTCACCTCCAAAATGCTGATGAACCTTTATACCTGAGCAAG AATGCAATTCTTACATGGGATGTTTAAACCAGCTATATTCTTCTGCTTTTGT CATTCTGAGTGTATGTGTGACTTCAATGGCTTATGATCGCTATGTGGCCATC TGTAAATCCACTCTGTACACGGTTGCCATGTCCCTAAATGTGTTTGAACCTTA TGCTTGGTACATATGCAATGGCATTTTCTGTGGTCCATGGCTCACACGGGATGCAT GCTGAGACTGACCTTCTGTGATGCTAACACCATCAACCACTACTTCTGTGACATC CTCCTGTGATGCAGCTCTCTGACCCAGCACCTATGTCAATGAGCTTGTAGTTT TCATTGTTGTGGGCATCAATATCATTTGTGCCAAGCATCACTATCTTCATCTCTTA TGGCTTCATCCTCTCAGCATTTTTCACATCAAGTCCAATGAAGCAGGTCCAAAG GCCTTCAGCACCTGCAGTTCCCATATAAATTGCAAGTTTGTCTCTTCTTGGATCAG GTGCATTTATGTATCTCAAAACCATCTTCTTCTCATCTATGGATCAAGGGAAC CTCTTCTGTGTTTATACAAATGTGGTTCCCATGATGAATCCCTTAATCTACAGTTT TAAGGAACAAAGATGTCAAGATAGCCCTGAGAAAACCCCTGAGCAGATGGAAA TTTTGAAAGGAGACAAC	MASANVSLVTEFILVGLT NQPDQLQPLFFVFLIMYIV TALGNLCILILVLSHLH TPMYFFLENLSTDLCYST VFTPKMLMNFILSKNAIS YMGCLTQLYFFCFFVISE CYVLTSMAVDYRYVAICN PLLYTVAMSPKLCNLML GTYAMAFSGAMAHTGC MLRLTFCDANTINHYFCD ILPVMQLSCTSTYVVELV VFIVVGINIIVPSITIFISY FILSSIFHIKSNEGRSKAFS TCSSHIIAVCLFFGSGAFM YLKPSSSSSMDQKGKTSSV FYTNVVPMMNPILYSLRN KDVKIALRKTLRSWKF

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069559_C	61/62	AATGGCCCTGGAAAAATGCTTCTTGTCACCTAGTTCATCTTGATGGGGTTAACA AACAGACCTGACCTACAAATACCCCTGTTCTACTCTTCTGGTGATGTACGTGA TAGCTACATTGGGGAAATTTAGCTTTGATCATGCTGATTATTCTGAATTCTCACCT TCACACTCCTATGTATTCTTCTCCTTAACCTTGTCCTGCATAGACCTTTTATTATT GTTTCAGTCAATTACACCTAAATGCTGATGAACCTTGTACTAAAGAAATGTTAT TTCTTATGAGGGATGATGGCCAGTCTATTCTTTGCTTCTTGTGCAATTTCTG AATGTTATGTGCTGACAAACAATGGCCTATGATCGCTATGTGGCCATTGCAATCC ACTCTTGACAAACATTGTAATGCTCCTAAGTGTGTTCTTATCTTATGATGGGT ACATATTTGATGGGGTTTCTGGTGCCATGATCCATCTGATGATCCCTAAGAC TGACATTCTGTGATAAAACACCATCAATCACTATTCTGTGACATCCCTCCCTT GCTCCAGATCTCCTGCACCATGACCTATGTTAATGAGATAGAGTTGTTCAATTGA GCAGGAAGGATAATTATTGTTCCCACTGTAAATCATCTTACCTCTTACGGCTTTA TCCTCTCCAGCATCCTCAAATAAAGCTCCACAGCAGGAATGTCCAAGCCTTCAG CACATGTAGCTCTCACATAATCGCTCTTTGTCTGTTCTTTGGATCATGTACATTTA TGATATCTAAACCCCTCCTCAGTTGAGTCTATGGACCGGGGAAAATATCTTCTGT CTTTTATAACATTGTTGTCCCTGATGAATCCATTAACTATATAGCCTTAGGAAC AAAGATGTTAAATGCTATAAAAAAACTATAACCAAGGAAAGTTTAAATCA GAATTT	MALENASLVTEFLMGLT NRPDLOPLFLFLVMYVI ATLGNLALIMLILNSHLH TPMYFFLLNLSCIDLFYCS VITPKMLMNFVLKKNVIS YEGCMAQFYFFAFFAISE CYVLTTMAYDRYVAICN PLLYNIVMSPKLC SYLMM GTYLMGFSGAMIHTGCIL RLTFCDKNTINHYFCDILP LLQISCTSTYVNEIELEIVA GKDIIVPTVIIFTSYGFILSS ILKISSTAGMSKAFSTCSS HIALCLFFGSCFTMYLKP SSVESMDQQKISSVFYNI VVPLMNPLIYSLRNKDVK IAIKKTITKGKF

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069559_A	63/64	AATGGTCGTGACAAAATGGCTCTTTTGGTAACAGAAATTCATTCCTTTGGGGTTAACA GATAACCCCTGACCTCCAAATACCCCTCTTTTAGTTTTCCTAGTAAATGTATATAGA TAACTGCCTTTGGGAATTTGACCTTTGATCCTCCTAACTGTGCTGAACCTCTCACCT TCATACCCCTATGTACTTTTTCCTCTTTAACTTGTCTTCATAGACCTCTGCTATT CTTCTGTGTACACCCAAATGCTGATGAACCTTGTACTAAAGAAAGAAATATTAT TGGTTTGGGGATGTATGACTCAACTCTACTTCTCTGTTTCTTGTATCTCTG AATGTTATGTCCTGACAGCAATGGCCTATGATCGCTATGTGGCTATCTGCAATCC ACTCATGTATAATGTTACCAATGTCCTAAAGTCTGTCTCTATCTTATGCTTGGTT CATATTTGATGGGATTTCTGATGCCATGATCCATCTGATGCATCCTGAGACT GACTTTCTGTGATGGGAACACCATCAATCACTACTCTGTGATCTTCTGCCCTTG ATGCAGCTTTCCTGCACAGCACCTATATAAATGAGGTAGAGATTTTTCATTTGTAG GGGAAAGATATCACTGTGCCAGTATTTGTCATCATCATTTCTTATGGCTTCAT CCTCTCTAATAATCTCCAAATAAAATCCACTGGGGCAGATCAAAAGCCTTCAAC ACCTGCAGTTCTCATATAATGCTGTCTCTCTGTTTCTGTTTGGGTGATGTGCAATTTAT GTACTTAAACCCCTCAGCTGATCTTTGATGAGGGGAAAGTATCTTCTGTC TTCTATACCAATTGTGGTCCCATGATGAACCCCTTTAATCTACAGTTTGAGAAATA AAGATGTTAAACTTGCCCTGAGAAAAACCTTTGAGCAGGAGAAAGTTTAAATGAT AAATTTATTATCTTT	MVVTNGSLVTEFILLGLT DNPDQLPFLVFLVMYM ITAFGNLTLILLTVLNSHL HTPMYFFLFNLSTDLCSY SVVTPKLLMNFVLKKNII GFAGCMTQLYFFCFFVIS ECYVLTAMAYDRYVAIC NPLMYNVTMTSPKVC SYL MLGSYLMGFSDAMIHTG CILRLTFCDGNTINHYFCD LLPLMQLSCTSTYINEVEI FIVGGKDITVPSIVIIISYGF ILSNILQIKSTGGGRSKAFN TCSSHIAVSLFFGSCAFM YLKPPSAGSLNEGKVSSV FYTIVVPMMNPLIYSLRN KDVKLALRKTLRRKF

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069563_D	67/68	ATGAAAGTCATGAAGCAAATGGTTACAGAAAGTAATCTTCAGTGACTGAGTTC ATTCCTATGGGATTAAACAGTTCAAAAAGAGCTCCAGTTGCCCTCTGTTCAATCCTAT TCTTGTTAAACTACACAGCCACTGTGTAGGAAACCTGAGCTTAATGAATCTCAT TTGCCATAATTCACATCTTCACACTCCCATGTACTTTTTCATCTTCAATCTGTCCCT GCATTGATTTTGTGTTATTCATTTGTTCTAACCCCAAAATGCTGAGGAGTTTGTGT ACAGAGCAGAACACCATATCCTATGAAGGATGATGATGACCCATGGCCTATGATCGCTA GCCTTTTGTAAACTCTGAATGTTATGTGCTGACAGCCATGGCCTATGATCGCTA CGTGGCCATCTGTCAATCCCTCAAGTACACAACTGTCTCTCCCTAAGATCTGC TGCTGCTGTTGTTGTTCTTACTTGTAGGGTTTGTGCTGGTGGCCTGACTCATA CAGGGTTATGATCAGGCTCAGTTTGTGTAATCTAACATCATCAACCACTACAT GTGTGACATCTTTCCCTCCCTCAGCTCTCTGTACTAGCACCTATGTCAACGAG CTTGTGAGCTCTGCTGTAGTTGGAAACAATATCATTTTATCTAGCATCATTTATTTT AGTCTCATATGCTATGATCCTTTCCAAATATCCTTCATATGTCTCAAGTAAAGGGT TGGTCAAAAAGCCCTGGGCACCTTGTGGGTCCACATCATAACTGTAGCCTCTTTT ATGGGTCTGGATTGCTTGCCTATATCAAGCCCAACATCTGTCTGAGACTGTGGACCA GGGGAAATTTTATCAATATTTTACACCTTGTGGTACCCATGCTGAATCCTCTC ATTTACAGCCTCAGAAACAAGGATGTCAAACCTTGCTCTGAAGAGAACAAATGAAA AGAGTCACAACCTGAATGAACA	MKVMKQMVTESNSSVTE FILMGLTVQKELQLPLFIL FLLNYTATVVGNLSLMN LILNSHLHTPMYFFIFNL SCIDFCYSFVSNPTMLRSF VTEQNTISYEGCMSQLFF FQFFVNSECYVLTAMAY DRYVAICHPLKYTTVMSP KICCLLVFGSYLMGFAGA LTHTFMIRLSFCNSNIIN HYMCDFPLQLSCTSTY VNELVSSAVVGTIILSSII LVSYAMILSNILHMSSSK GWSKALGTGSHIITVSL FYGSGLLAYIKPTSAETV DQGKFLSIFYTLVVPMLN PLIYSLRNKDVKLAKRT MKRVTT

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069563_C	69/70	GAATGGCCTCTGGCAATGACTCCACACAGTGAAGGAGTTTATTCGTGGGCTT GACACAGCAACAGAGCTCCAGCTGCCCTTCTTCTCCTGTTCTTGGGAATCTAT GTGGTCTCCATTGTGGGAACCTGGGCTTGATTGTTCTGATTGTTTGAATCCTC ACCTGCACACCCCCATGTACTACTTCTCTTCAACCTTTCCTTCATTGATTCTGTC TACTCCTCTGTCTATAACCCCCAAATGCTGGTGGTGTGTAACACAGAATATCA TTTCTCATGCTGAGTGCACTGACTCAACTCTTTTCTTGCCTTCTTGTATTGAT GAATGTTGTAATTTGACAGCAATGTCCATGACAGATATGTGCCCATATGTAAGC CATTGCTTTATAAGGTTACCATGTCCATCAGGCTCTGCTTCATGATGACAGTGAG TGTTGACATGATGGGTTTGTGGTGCCATAGCCCCACACAATTGCGATGCTGAG ACTCACCTTCTGTGATGGCAACATCAATTAATCACTACATGTGTGACATACCCCT CTCCTGAAGCTCTCCTGCACAAACACCTCTGTCAATGAGCTGGTGTTCATTG TTGTGGGTGTCATGTGATAGGACCTACATTTGATCATCTTTACTTCTTATACCTT GATCATTTTCAACATTTACATATCCGTTCCACTGAAGCAGATCCAAGGCTATT AGTACCTGTAGCTCGCACATAATAGCTGTTTCTATTCTTTGGAGCCTCAGCAT TCATGTATCTTAAGCCTTCTCCTGTTGGATCTGTGGTGAAGATAAAGTATCTAC GGTTTCTACACCATTTGTGGGCCCGATGTGAACCTTTTCATCTACAGTTTGAGG AACAAGGATGTCCACATTCGCACTGCATAAGACTTTGAAGAAAAGCATGCTTATC TAGATAGAAACTTTTTTCTCTCTAGATTCAGATCTTACAT	MASGNDSTTVKEFILLGL TQPELQLPFFFLFLGIYV VSIVGNLGLJVLIVLNPHL HTPMYVYFLFNLSFIDFCYS SVITPKMLVGFVKQNIISH AECMTQLFFFAFFVIDEC CILTAMSYDRYVAICKPL LYKVTMSYQVCFMMTVS VYMMGFVGAIAHTICML RLTFCDGNIINHMYMCDIPP LLKLSCTNTSVNELVVFIV VGVNVIGPTLIIFTSYTLII FNISHIRSTEGRSKAISTCS SHIIAVSIFFGASAFMYLK PSPVGSVGEDKVSTVFYT IVGPMLNPFIYSLRNKDV HIALHKTLKKSMLI

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069563_A	71/72	CAAATAACTATGGAAATGACTCTTTTGTGTCTGAATTTATCCTTATGGGACTGA CAGATCATCTGAACTCCAGTTGCTCTGTTTGTCTCTTTTGTGATGAACACTACACA GCCATTGTGATGGGAAACTTGAGCTTAATGATCTCATTTTCTTGAATTCAAACC TTCACACCCCATGTACTTTTTCATCTTCAATTTGTCCTTCATTGATTTTGTGTTAT TCATTGCTCTTTACCCCAAGATGCTAATGAGCTTTTTTAGAGAAAAACACCA TCTCCTTCAGAGGATGATGACTCAGCTGTTCTCTCTCTCTTTTGTGAACCTCT GAGAGTTATGTGCTGACAGCCATGGCTACGATCGCTATGTGGCCATCTGTAAG CCTTTACTATACAAGACTATCATGGTACCTAGGATCTGTGCTCTCTGATGTTTG TTTCATATTTGATAGGTTTACTAGTGCCATGATCCTCACAGGCTTAATGTTTAG GCTCAACTTTTGTAATAACCATCATCAATCACTACATGTGTGATATCTTCCCT GTCAATTCAGATCTCCTGCAGTGACACCTATCTCAATGAGCTTGTAGTACTGCTG TGGTAGGTACAGGTATCATTTTATGTAGCCTCCTTATCTTAATGTCTTATGCTCT GATCCTTTTCAATATCCTTAATATGTCTCAGGTAAGGGTTGGTCCAAAGCCATG GGCACTTGTGGCTCCCATCATATAACCGTTAGTCTCTTTTATGGGTCTGGGCTCC TTGCTTATGTCAAAGCCATCATCTGCTGAGACTGTGGGCCAGGGAATTTTCTC ACTGTTTATACATTTCTCGTGCCCATGTGTAATCCTCTCATATACAGTCTCCAG AACAAAGATGTCAAAGTTGCTGTGAAGAAAAACCTTGAAGAGAATCTCAAAATTGA CTCAACCACTGGCACTTCACAGAACCCCT	MENDSFVSEFILMGLTDH PELQLSLFVFLMNYTAI VMGNLSLMILFLNSNLH TPMYFFIFNLSEIDFCYSF VFTPKMLMSFFLEKNTISF RGCMTQLFFFCFFVNSES YVLTAMAYDRYVAICKP LLYKTMVPRICLLMFV SYLIGFTSAMILTGLMFRL NFCNNHHNHMYMCDIFPVI QISCSDTYLNELVSTAVV GTGILCSLLILMSYALILF NILNMSSGKGWSKAMGT CGSHIITVSLFYGSGLLAY VKPSSAETVGGQKFFSLF YTFLVPMNLNPLIYSLQNK DVKVAVKKTKLKRISN

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC026975_C	73/74	CTCCTGTGCTTTAAATATAGTTTGCTACAAACAATGTGACTGAAATAATTTTCGT GGGATTTTCCAGAAATTGGAGTGAGCAGAGGGTCATTTCTGTGATGTTTCTCCTC ATGTACACAGCTGTTGTCTGGGCAATGGCCCTCATTTGTGTGACCATCCTGGCCA GCAAAGTGTCACTCCCTCCCATGTATTCTTTCTCAGCTACTTATCCTTTGTGGAG ATCTGCTACTGTTCTCAAGGGCTGCCCTCACACAGATGTTTCCCTCCATTCTT GGAAAGTCAATTCTCTCAAGGGCTGCCCTCAGCCATGATGACCGCTATGTGGCC TGGTGGCACTGAGGCCCTTCTCTGATGGTGCATGACCCGCAATGTGTGGTCTCC ATCTGCAAGCCCTTGCACTACATGGCCATCATGAACCAAGCAATGTGTGGTCTCC TCGTGAGGATAGCATGGGGGGGGCTGCTGCATTTCTGTGGCAAAACCTTCC TGATTTTCCAGCTCCGTTCTGTGGCCCCAACATCATGGACCACTACTTCTGTGA TGTCACCCAGTGGAGCTGGCTGCCCTGCCAGACACCTTCTTCAATTAGCCTGCTG ATCATCACCAATGGCGGCTCCATCTCCGTAGTCAGTTTCTTGTGCTGATGGCTT CCTACCTGATCATCTGCACTTCTGAGAGCCACAACCTTGGAGGGGCAGCACA AGGCCCTCTCCACCTGTGCCCTCTCATGTACAGTTGTGACCTGTCTTCTCATACCT TGCTCCTTGGTCTATATTAGGCCCTGTGTCAACCTCCCTGCAGACAAGATAGTTG CTGTATTTTATACAGTGGTCACACCTCTCTTAAACCTGTGATTTACTCCTTCAGG AATGCTGAAGTGAAAAATGCCATGAGGAGATTATTGGGGGAAAAAGTAATTGA GAAGAGAA	MVATNNVTEIFVGFSSQN WSEQRVISVMFLLMYTA VVLGNGLIVVTILASKVL TSPMYFFLSYLSFVEICYC SVMAPKLIFDSFIKRVIS LKGCLTQMFLSHLFFGGTE AFLLMVMAYDRYVAICK PLHYMAIMNQRMCGLLV RIAWGGGLLHVSQGTFLL FQLPFCGPNIMDHYFCDV HPVLELACADTFISLLIT NGGSISVVFFVLMASYLI ILHFLRSHNLEGQHKALS TCASHVTVVDLFFIPCSLV YIRPCVTLPADKIVAVFY TVVTPLLNPNVIYSFRNAE VKNAMRRFIGGKVI

Table 1

Acc. No.	SEQ ID NO (NucI) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
CG55991-01	75/76	CTCCTGTGCTTTAAATAATAGGTTGCTACAAACAATGTGACTGAAATAATTTTCGT GGGATTTTCCAGAAATTGGAGTGAGCAGAGGGTCAATTTCTGTGATGTTTCTCCTC ATGTACACAGCTGTTGTGCTGGGCAATGGCTCATTTGTGTGACCATCCTGGCCA GCAAAGTGCTCACCTCCCCCATGTAATTTCTTCTCAGCTACTTATCCTTTGTGGAG ATCTGCTACTGTTCTCATGGCCCCCAAGCTTATCTTTGACTCCTTTATCAAGA GGAAAGTCATTTCTCAAGGGCTGCCCTCACACAGATGTTTCCCTCCATTTCTT TGGTGGCACTGAGGCCTTTCTCCTGATGGTGTATGGCCTATGACCGCTATGTGGCC ATCTGCAAGCCCTTGCACTACATGGCCATCATGAACCAAGCAATGTGTGGTCTCC TCGTGAGGATAGCATGGGGGGGGCTGCTGCATTTCTGTGGCAAAACCTTCC TGATTTTCCAGCTCCCGTTCTGTGGCCCCCAACATCATGGAACCACTACTTCTGTGA TGTCACCCAGTGCTGGAGCTGGCCTGGCAGACACCTTCTTATTAGCCTGCTG ATCATCAACAATGGGGCTCCATCTCCGTAGTCAGTTCTTCGTGCTGATGGCTT CCTACCTGATCATCCTGCATTTCTGAGAACCAACTTGGAGGGCAGCACA AGGCCCTCTCCACCTGTGCTCCTCATGTCAAGTTGTGACCTGTCTTCTCATACCT TGCTCCTTGCTCTATATTAGGCCCTGTGTCAACCCCTCCCTGCAGACAAGATAGTTG CTGTATTTTATACAGTGGTCACACCTCTCTTAAACCCCTGTGATTTACTCCTTCAGG AATGCTGAAGTGAAAAATGCCATGAGGAGATTTATTGGGGGAAAAAGTAATTTGA GAAGAGAA	MVATNNVTEIFVGFSSQN WSEQRVISVMFLLMYTA VVLGNGLIVVTILASKVL TSPMYFFLSYLSFVEICYC SVMAPKLIFDSFIKRVIS LKGCLTQMFSLHFFGGTE AFLLMVMAVDYRYVAICK PLHYMAIMNQRMCGLLV RIAWGGGLLHVSQGTFLL FQLPFCGPNIMDHYFCDV HPVLELACADTFFISLLIT NGGSISVVSFFVLMASYLI ILHFLRSHNLEGQHKALS TCASHVTVVDLFFPCSLV YIRPCVTLPADKIVAVFY TVVTPLLNPVIYSFRNAE VKNAMRRFIGGKVI

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC037472_A	79/80	CAATGGATAAAGAAACAGCTCAATGGTGACTGAGTTTATCTTCATGGGCATCA CCAGGACCCCTCAGATGGAGATCATCTTCTCGTGGTCTTCCTCATAGTTTACCT GGTTAATGTAGTGGGAATATTGGTATGATTATCCTGATTACAACAGACACTCA GCTTCACACACCCATGTATTTTTCCTCTGCAACCTCTCCTTTGTTGACCTGGGCT ACTCCTCAGCCATTGCCCCAGGATGCTGGCTGACTTCTTAACAAATCAACAAAGT TATCTCCTTCTCCAGCTGTGCCACCCAGTTTGTCTTTTGTAGGTTTGTGGATG CTGAGTGCTATGTCTGGCAGCCATGGCCTATGGTCTGTTTGTGGCCTCTCATGCTG ACCCCTCCACTATAGCACCTTCTAGTCAAGCAGGTCTGTTGGCTCTCATGCTG GGCTCTTACCTGGTCTAGTCAAGTCTAGTCAAGTCTGTTGGCTCTCATGCTG GCCTGAGTTACTGTGGTCCCAATATCATCAATCAATTTCTTCTGGAAATCCCAAC ACTCTTGGCCCTCTTGTCTCAGACACCTACATCAGTGAATCTTGTCTCTTCACT CTGTGTGGCTTCAATTGAATTCAGCACCATCTCATCTTCTCATCTCTATACCTT TATCCTTGTGCAATCATCAAGATGCGTTTCAAGTGAAGCCGCTTAAGGCTTTC TCCACCTGGGGTCTCAACCTTACTGGCATCACCTCTTCTATGGCACAGTCAATGT TTATGTACCTGAGGCCAACATCCAGCTACTCCTGGACCAAGACAAAGTGGGCCT CTGTGTTCTACACGGTTATCATCCCCCATGTTAAATCCCTTGATCTACAGTTTGGC GAACAAAGGATGTGAAAGCTGCTTTCAAAAAGCTAATTGGAAAAAAATCTCAATA ATAACACAAAAATGAAAATCT	MDKENSSMVTEFIEMGIT QDPQMEIIFVFLVYL NVVGNIGMIILITDTQLH TPMYFFLCNLSFVVDLGYS SAIAPRMLADFLTNHKVI SFSSCATQFAFFVGFVDA ECYVLAAMAYGRFVAIC RPLHYSTFMSKQVCLAL MLGSYLAGLVSLVAHTT LTFSLSYCGSNIINHFCEI PPLALSCSDTYISEILLFS LCGFIEFSTLIIFISYTFILV AIIRMRSAEGRKAFSTC GSHLTGITLFYGTVMFMY LRPTSSYSLDQDKWASVF YTVIIPMLNPLIYSLRNKD VKAAFKKLIGKKSQ

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_G	81/82	AATGACTTTTGGAAAATGCTTCTATGGTAATTGAATTCATCTCTTGGGGATAACA GACCAACCTGACCTCAAAATTCCAATTTTCTCTACTCTTTTGTAGGATACATGA TAACTGTGTGGGAAAATTGACCTTGATCATTTTAAATTGGGCTAAATTCACACCT CCACACACCATGTACTTCTCTTGTGTTAACTTGCTCTTCAATTGATCTCTGTTATT CTTCTGTGATTACACCAAAATGCTGATGAGCTTTATACAAAAGAAATATTAT CTCTTATACAGGGTGATGATCCAGTTATCTCTTTTGTCTTTTGTCTCTCTG AGTGTATGTGCTGACCTCAATGGCCTATGATCGCTATGTGGCAATCTGCAATCC ACTGTTGTATAATGTTACCTTGTCTTCTAAGGTATGTTGTTATCTGATGCTTGTT CGTATTTTCATGGGATTTCTGGTGCCATGATACACACTGGATGATTTCTAAGACT GACATTTTGTGATGGAAATACCATCAACCACTAATTTTGTGATCTCCTCCCTTG CTGCAAAATCTCCTGTACAGCACCTATATCAATGAGATAGAGCTGTTTCATTGTAG CAGGAAAAGACATAATTGTACCCACTATCATCATCTTTATCTCTTATGGCTTCAT CCTCTTCAGTGTCTCAAAATAAAATCCACTGAAGCAGGTCTAAAGCTTTCAGC ACCTGCAGTTCCCATATGCTTGTCTGTTTCTCTCTTCTTGGATCAGGTGCATTCT GTATCTTAAACCTACCTCAGCTCTATCTATCAATAAGGGGAAATCTCTCTCTCT TTTTATACCATTTGTTGTTCCCATGATGAACCCCTTTAATTTACAGCTTGAGGAACA AAGATGTTAAAGCTGCCCTGAGAAAGACTTTGAAACAGGAGAAATATTTTCATCAT AAACTGGATATCTCTGAGCCTACACTTAAACAATAGAGAGATT	MTFENASMVIEFILLGITD QPDLKIPFFLLFFVGYMIT VLGNLTLLILGLNSHLHT PMYFLLFNLSFIDLCSYSSV ITPKMLMSFIQKKNIISYT GCMQLYFFCFVISECYV LTSMAYDRYVAICNPLLY NVTLSKVCCYLMGLSYF MGFSGAMIHGTGILRLTF CDGNTINHYFCDLLPLLQI SCTSTYINEIELFIVAGKDI IVPTIHFISYGFILFSVLKIK STESRSKAFSTCSSHMLA VSLFFSGGAFMYLKPTSA LSINKGKFSFLFYTIVVPM MNPLIYSLRNKDVKAALR KTLNRRIFSS

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_F	83/84	AATGGACTCAGTAAATATTTCTTTGGTGACTGAATTCATTCTGGTGGGATTAACT GACAAGCCTTATCTACAATAACCCCTTGTTCTTTATATTTCTGGCAATGTACCTAG TCACTGCATTGGGGAATTTATCTTTGATAATACTGTGTGAATCTCACCT TCACACCCCTATGTACTTTTCTCTCTTTAACTTGCTCTTTGTAGACTTCTGCTATT CTTCTGTGTTCACTCCACAAATGTTGATGAACCTTTATAACAAGGAAGAAATACAAAT TTCTTACATGGAATGATGAGCCAACTTTATTTCTTTTGTGTTTGTGTTATTTCTG AGTGTATGTGTTGACTTCAATGGCCTATGATCGCTATGTGGCATTGTGAAACC ACTGCTGATAATCTTGTCAATGCTCTAAATATGTTTGAACCTAATGCTGTTT CCTACTTTATTGCAATTTCTGAGTCTGTGGCTCACACTACTTCTGTGATATCCACCTTG GAACCTCTGTGATGCCAACAAATCAACCACACTACTTCTGTGATATCCACCTTG CTCCAACTTTCTGTACACCAACATATATCAACAAGCTGTAGTTTGTGCTTC TAGCATCAATATCATGTTCCCATTTCAACTATATTTATTTCTATGTTTTATTCT TCTCCAGCATCTTTCACATCCATTCTCTGAAGCAGGTCCAAAGCTTTCAGCAC CTGTAGCTCACACATCATGCTGCTTTCTGTTCTTTGTTTCAGGTGCATTATGT ATTTCCAAACCATCTCAGCTGAGTCTATGGATGAAGGAAAAATCTCTTCTGTCTT TTATACTAAATGTGATTCCCATGATGAATCTCTACTCTACAGCTTGAGGAACAAA GACATAAAAGTGGCTCTGAGGAAAAACCCCTGAGCAAGAGGAACATTAACT	MDSVNISLVTEFILVGLTD KPYLQIPLFFIFLAMYLVT ALGNLSLILTVLNSHLHT PMYFFLFNLSFVDFCYSS VFTPQMLMNFITRKNITIS YMECMSQLYFFCFFVISE CYVLTSMAYDRYVVAICK PLLYNLVMSSKLCNLML VSYFIAFSESVAHTVCIMR LNFCDANKINHYFCDIPPL LQLSCTTTYINKLVVFVA SSNIIVPISTIFISYGFILSSI FHHSEGRSKAFSTCSSHI IAAFLFFGSGAFMYFQPSS AESMDEGKISSVFYTNVIP MMNPPLYSLRNKDIKVA LRKTLSKRNI

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_E	85/86	GTGCAAAATGGCAGATACAAAATCACTCCACAGTGACTGAGTTTCATCCTTGCTGGA TTAACAGACAAACAGAGCTGCAGCTGCCCTCTCTCCTCTCTCTTCTTGGAATCT ACCTGCTCACAGTGTGGGGAACCTGGGCAATGATCATCTGATCCTGCTCAGCTC CCACCTGCACACCCCCCATGTACTTTTCCCTCAGCAGCCTGTCTTCAATTGACCTCT GTTACTCCACTGTTATTACCCCGAAGATGTGGTGAACCTTGTGGCAAGAAGA ATGTCATCTCCTATGAGGAATGTATGACTCAGCTCTATTCTCTCTGCTTTTGT ATATCTGAGTGCACATGTTGGCTGCAATGGCATAATGACCGCTATGTTGCCATT GCAATCCCCTTGCTTTACAAATGTCACATATGTTACCAAACTGTCTCCTGGATGGT AGTGGGGTATATGGCATGGGTTTAAATGGTGCAGCAGTTCATACTCTCTGCATG CTAAGAGTGGTTTCTGTAAAGGCTAATAATAAACCACTTACTTCTGTGATCTTT TCCCATTTGATGGAGCTTGCTGCTCCAGTACTTATGTCAATGAGGTAGTACTCCT GTGTCTCAGTGTCTTCAATATCTTTATTTCCAACTTCAATCCAGGAAGGCAGATTCAAAGC TCTTCATCATCATTAGTATCCTCCGTATCAAAATCCAGGAAGGCAGATTCAAAGC CTTCAGCACATGTAGCTCCCACTTCTCTGCTCAGCTCCAAAGACAAAGCAAGTGTCT CATTCATGTATCTGCAGCCCCCTTCTCTGTCTCAGCTCCAAAGACAAAGCAAGTGTCT CTCTGTGTTTACACTACTATTGTGCCCATGCTGAACCCCATGATCTATAGCCTG AGGAATAGGGATGTTAAACTTGCTCTAAATAAGTTATTTCAAAGAAATTCCTCAT GTGTAAAGAA	MADTNHSTVTEFILAGLT DKPELQLPLFLFLGIYLL TVLGNLGMILLSSHLH TPMYFFLSSLFIDL CYST VITPKMLVNFVAKKNVIS YEECMTQLYFFLAFVISE CHMLAAMAYDRYVAICN PLL YNVMTMSYQCSWMV GGVYGMGLIGAAVHTLC MLRVVFCANIINH YFCD LFPLMELACSTYVNEVV LLCLSAFNIPITLTILGSYI FIISILRIKSTEGRFKAFST CSSHFSASVSVFFGSLAFM YLQPFSSSKDKGKVSSV FYTTIVPMLNPMIYSLRN RDVKKLALNKLQKKPHV

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_C	87/88	AATGGCTCTAGTAAATGGCTCAACTGTGACTGAATTCATTCCTTTGGGATTAAACA GACCAGCCTGGACTCCAAATGCCTCTTTCTTATTGTTCTATTAAATGTACATGA TCACAGTATTCGGTAAATTTGACTTTGATATTTTAAATTCCTGTTAAATTCCTCACCTA CATACTCCCATGTATTTTCTCTTGAATTTATCTTTTGTAGATCTCTGTATTCTC TTCTGTGATTACACCAAAATGCTGATGAATTTATACATAAGAAAGAAATCTTATC TCTTATATGGGATGATGCCCCAACTCACTCTCTTTGTTTTCATAAATTTCTGA ATGTTATGTACTGGTCAATGGCCTATGATCGCTATGTTGCAATCTGTAATCCA CTGTTGTATAACACTGCCATGTCCCCAAGGTGTCTTATCTCATGCTTGGA CATATTTGATGGGATTTTGTGATGCTATGATCCATCTGTTGCTGCTCAGACT GAGCTTCTGTGATGGCAATATCATCAACCACTATTTCTGCGATGCTCCCTTTG CTGCAGCTCTCTGTACAGCACCTATGTCAATGAGACAGAAATTTTCATTGTAG GGGAAAGACATCATCTTCCCAGTGCCATTATCTTTTCTCTTATGGCTTCAT TCTCTCAACATTTTCCAAATAAGATCCACTTTGGGCCGGTCCAGGCTTCAGC ACTTGCAAGTTCCCATATAAATTGCTGTCTCTCTGTTTGGATCATGTGGATTTCAT GTACCTGAAACCTTCCTCTGCTGTATCTATTGATCAAGGAAATAATCTCTTCCATT TTTTATACCATTTGGTTCCTATGATGAACCCCTAATTTATAGCTTGAGAAACA AAGATGTTAAAGTTGCCCTAAGAAAGACTTTGAGTAGGAGGAAGTTTTTAAAG TATAGTTGCAAA	MALVNGSTVTEFILLGLT DQGLQMPFLFLFLMY MITVFGNLTLFLILLNSH LHTPMYFFLLNLSFVDLC YSSVITPKMLMNFILKKN LISYMGCMSQLYFFCFH SECYVLVSMAYDRYVAI CNPLLNTAMSPRVCSYL MLGTYLMGFFDAMIHTG CMLRSLFCGDNINHYFC DVLPLLQLSCTSTYVNET EIFIVGGKDILPSAIFSY GFILSNIFQIRSTLGRSKAF STCSSHIAVSLFFGSCGF MYLKPSSAVSIDQKISSI FYTIVPMMNPLIYSLRN KDVKVLRKTLRRRKFL KV

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_B	89/90	TAATGGCTTTGATAAAATGGCTCTGTGGTAACAGAAATTCATCTCTGGGATTAACA GACCAGCCTGACCTTCAAGTACCCCTGTTCTCTGCTTCTTCTAATTAATGACATGA TAACTGCATTTGGGAATTTGACTTTAAATTAATTCATCTGCTGCTGAATTCCTCACCT TCATACCCCTATGTATTTTCTTTTAACTTGTCCCTTGTGGACTTTTGTGTTACTC TTCTGTAATTATACCAAAATGCTGATGAACCTTATCTAAAGAAAAATTTTATC TCCTATGTGGTGTATGACTCAGTCTACTTATTTGGTTTCTGTGTCATTTTGGGA GTGTTATATTCACATCAATGGCCTATGATCGTTATGTGGCTATCTGCAATCCA CTCTTGATAACATTTGTCATGCTCCGAAGATGTGTTCTCTATCTCATGCTTGGTTC ATATTGATGGGGTTTCTGGTGCTATGATCCACACTGGATGTGCTGAGACTG TCGTTCTGTGATGGCAACATCATCAACCACTATTTCTGTGATCTCCTCCCTTTGCT GCAACTCTCTGCACCAACCACTATGTCAATGAGATAGAGGTGTTAATTGTAGC AGGGAAGGATATCATTTGTGCCCACTGTGATCATCTTATCTCATATGGCTTCATC CTTTCCAGCATATTTCAAAATGAAAATCCACTAAGGCATGTCAAAGCCTTCAGCA CCTGTAGTTCCACATAATTGCTGTCTCTCTGTTCTTTGGATCTGGTGCAATTATG TATCTTAAACCCCAACTCAACTGGAACAATGAACAATGGAAGATACCTTCAATA ATTTATACCATCTTAATTCCTATGATGAATCCATTAATTTATAGCTTGAGAAACA AAGATGTTAAAGTTGCCTTGAGAAAAACCTTTGAGAAAAAGAAAATCTTGTAAATCAG AAACT	MALNGSVVTEFILLGLTD QPDLOVPLFLVFLLMYMI TALGNLTILILVLSHLH TPMYFFLENLSTVDFCYSS VIIPKMLMNFILKKNFISY VGCMTQFYLFQFCVILEC YILTSMAFYDRYVAICNPL LYNIVMSPKMC SYLMLG SYLMGFSGAMIHTGCVLR LSFCDGNIINHYFCDLLPL LQLSCTSTYVNEIEVLVA GKDIIVPTVIIFISYGFILSSI FQMKSTKGMSKAFSTCSS HIIAVSLFFGSGAFMYLKP NSTGTMMNKGIPSIHYTILI PMMNPLIYSLRNKDVKV ALRKTLRKKIL

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC069561_A	91/92	GAAGAAATGGCTCTGGCAAATGGCTCTTTGTAACTGAAATTCATTCCTCTTGGGCTT AACAGACGAGCTGACCTTCAAATAGCCCTGTCTCTAAATTTTCTAATAATTTAT TTGATAACAGCATTTGGAAATTTGACTTTAATAATTTAATTTGTTGAAATCTC ACCTTCACACACCCATGTACTTTTCCCTCTTTAACTTATCCTTCATAGATCTTTGCG TATTCTCTTTGATCACACCCAAAATGCTGATGAACCTTTGTACTAGAGAGAACA TTATTTCTTACATGGGTGCTGACAGCAATGGCTATGATCGCTATGTGCGCATTTGTA TCTGAATGTTATGTGTGCTGACAGCAATGGCTATGATCGCTATGTGCGCATTTGTA ATCCACTCTTGTATAGTTGCGCATGTCTCCAAAGATGTGCTCTATTTTATCTT GGTTCATATTTCAATGGGATTTTCAGGTGCCATGATCCACACAGGTGTGTAATGA GACTGACCTTCTGTGATGGAACACCATCAACCATTAATTTGTGATCTCCTCCC TTTGCTGCAACTCTCTGACCCAGCACCTATGTCAATGAGATAGAGTTGTTTAT GTAAAGGAAAGACATCAATGTGCCCCACTGTGATCATCTTTGCTTCTTATGGCT TTATCCTCTCCAATACTCTCAAAATAAGGTCCACTTCAGGCAGGTCCAAAGCCTT CAGCACTTGCAGTTCCACATAAATGTGTTTCTATGTCTTTGTTTCAAGTGCA TTTATGTATCTCAAACTTCTTCAGCTGTATCTATGAATGAGGCAAAAGTTCTCTT CCATATTTTACAGCAATGTGGTACCCATGATGAACCTCTAATCTACAGCTTGAG GAATAAAGATGTCAAAGTTGGCTTGAAAAAACCTGAGCAGAAATGTTTAGTCA TAACCTAATCTCATTATAGATATAACACAGAAATCTTATATTA	MALANGSFVTEFILLGLT DQPDLMPLFLFLIYLI AFGNLTLILVLNSHLHTP MYFFLNLSTDLCSLI TPKMLMNFVLEKNIISYM GCMTQFYFFGFFAISECY VLTAMAYDRYVVAICNPL LYSVAMSPKMCYFILGS YFMGFSGAMIHTGCVMR LTFCDGNTINHYFCDLLP LLQLSCTSTYVNEIELFV TGKDIIVPTVIEASYGFIL SNILKIRSTGRSKAFSTCS SHIAVSMFFGSSAFMYLK PSSAVSMNEAKFSSIFYSI VVPMMNPLIYSLRNKDV KVGLKKTLSRMFSHNLIS L

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073434_C	93/94	ACCATGGAAGAATTAAATCATACCTCAGTGACAGAGTTCATTCTTGCTGGTTAA CAGAGAAATCCAGAGCTCCAGTTGCCCTCTATTCCCTTACCTTCCTATCTGTCTATTG TTTACAGTTGTTGGAAACCTTGGCATGATTGTATTGATTCTGATTAGTTCTCAGC TACATACACCTATGTATTATTACTCAGCAGTCTGCCCTTATTGACTGCTGTCA GTCTACTGTCAATTGTTCCCTAAATGCTGTTGAACTTTGTGACAGAGAAAGATGTC ATCCTGTACCCAGAAATGCATAGCTCAGTTCTATTCTCTGTACTTTTGTGTGTC AGAATGTCACATGTTGGCTGCAATGGCATATGACCGCTATGTGGCTATATCTAAC CCTTTGCTTTACAAAGTACCCATGCTCTATCAAGTCTGTTGTTGATGGTAGCTG TGGTGATGGTATTGGCTTAATCAGTGCCACAGCTCACACAGTCTTCTGCTAAG ATTGTTTTTCTGTAGGCTGATAAAATAAACCACTACTTTTGTGATCTTTCCCAT TACTTGAGCTGCTTGCTCTAGTACTTTATCAATGAAATATTAGCACTGTCCTTC AGTGCAATTAATATTATTGTACCGCCATGACCATCATTTGGCTCTTACATCTTCA TCATTATCAGCAATTTTGACATTAAATCCTCTGGGGCAGAGTCAAGGCCTTTAG AACCTGCAGCTCCCATATCTTGGCTGTGCTATTCTTTGGTTCTACAACATTCA TGTAATCTACAACCATCTTCAGTCAGCTCCATGGACCAAGGAAAGTGTCTATCTGT GTTTTATACCAATTGTTGCTCTATGTTGAATCCCATGATCTACAGCCTGAGAAAT AAAGATGTCAAAGTTGCCCTAAAAAAGTTACTACAAAGATGTTTCTCTCAAAAC AAGGAATAGATTTTCTTGGAATTAATCTGCA	MEELNHTSVTEFLAGLT ENPELQLPLFLTFLSVYLF TVVGNLGMIVLILISSQLH TPMYYLLSSLFIDCCQST VIVPKMLLNFTVTEKNVIL YPECIAQFYFFCTFVVAEC HMLAAMAYDRYVAISNP LLYKVPMSYQVCLLMVA VVYGIGLISATAHTVFLLR LFFCKADKINHIFCDLFP LLELSCSSTFNEILALSFS AFNIIVPAMTIIGSYIFIISI LHIKSSGGRVKAFRTCSS HILAVAIFFGSTTFMYLQP SSVSSMDQKGKVSFVYTI VVPMLNPMIYSLRNKDV KVALKKLLQKMFQNKE

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073434_A	95/96	GACATGCCAGCAGGAAACCAATGTCACAGTGACTGTGTTCTTCTTAGCTGGGCTCT CAGAGCAGTCAGAACTCCAGCTGCCCTGTTCCTCTTCTCACAGGAATCTATCT GATCACTGTGCTGGGAATCTGGGCATGATTACTAATTGGGCTCAGTTCCAAAC CTGCACACACCCATGTAATAATTTCCCTCAGCAGTTTGCTCTCATTTGGTCA GTCCACAGTTGTTACCCCTAAAATGCTGGTGAGCTTTCTGACAGAGAAGAACCTC ATCACCTACCTGAATGCTTGGCTCAGCTCTACTTTGCCATCATTTTGGCACAG CAGAGAGCTACACATTAGCTGCAATGGCATAATGACCGCTATGTTGCCATCTGTA ACCCCTGGTTTACAATATAGCCATGTCCTCTCAGATTACTGTTCTCTGATTCA GGGTATACATTTTGTGTTCTGTGCATCAGTAACACATGGGCTTCATGTTTA GGATCCAGTTCTGCAATCAGATGTAATCAACCACTATTTCTGTGATTCTATTT CCTCTGAAACTTGCATGCTCTAATACATAATGTCAGTGAATGTTGATTCTATTT TTTGGTACACTGAATATCTTTGTCCCAATAGCTCTAGTAGGGCAGGTCCAAAGCCTTT CATTATTTCCAGCATCCTCCGCATTAGCTCTAGTAGGGCAGGTCCAAAGCCTTT AGTACTTGCAGTCCACATCTCTGCTGTTGCTGCTCTATGGTTCTACAGCATT TGTTACTTACAGCCATCAGGATAAGTTCAATAGACCAGGAAAGTGTCCTC TGTTGTTTATACGACTGTTGTTCCCATGCTGAACCCCTTGATCTACAGCCTGAGG AATAAGGATGTCAGTGTGCAATGAAGAAAATACTTGAAAGGAAAAGATTTCATG TAAGCAGAA	MPAGNHCTVTVFFLAGLS EQSELQLPLFLEFFTGIYLLT VSGNLGMILLIGLSSNLHT PMYYFLSSLSFIDFGQSTV VTPKMLVSFLTEKNLITY PECLAQLYFAIIFGTAESEY TLAAMAYDRYVVAICNPL VYNIAMSSQIYCSLISGVY IFAVFCASVNMGMFMFIQ FOKSDVINHYFCDLPLL KLACSNITYVSEMLILFFG TLNIFVPMLTIIISYISHSI LRISSEGRSKAFSTCSSHI SAVAVFYGSTAFVYLQPS RVSSIDQKGKVSSEVFYTTV VPMLNPLIYSLRNKDVSV AMKKILERKRFM

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_H	97/98	AACATGGAAAAAGGCAATCAATCCACAGTGAACAAATCTTCTTCTGGCTTA ACAGAACAAACCAGAACTGCAACTGCCACTTCTCTCTTCTTCTGGAAATCTACC TGCTCACAGTGTGGGAACCTGGGCATGATCATCTGTATCCTGCTCAGCTCGTA CCTGCACACCCCTATGTACTTCTTCTCAGTAGTCTGTCCCTTCATTGACTTCTGCC AATCTACTGTCAATACCCCAAAAATGCTGGTGAATTTGTAGGGAGAGAAGATG AAATCTCTTACCTGAGTGCAATAACTCAACTTGTCTTCTTGTCTATTTTGTCTGT TCAGAAAGTTACATGCTGGCTGCAATGGCATATGATGCTATGTTGCCATCTGTA GCCCTTACTTTACAGTAGCATCATGTCTCAACATAAGTGCCTTCTCTCGTTTAA GGAGTTACATTTAGGCATAGTTTGTGTCATCAGCTCATGTAGGATGATATTTA GGATTGATTTCTGCAATCTGATTTGATCAACCAATATTCTGTGACCTTATTTCT ATTCTTAATCTCTCATGCTCTAATATTTTGTGAATGATCTCGTAATCTCAATTT TAGTCTAAATTAATACCAATTTTCCCAACCCTGACCATCCTCAGTTCTTATGCTTCA TCATTATCAGCATCCTAGGCATTAATCCACTGAGGGAAGATCTAAGCCTTCAG TACCTGCAGCTCCACATCTCAGCTGTGCTATCTTTTATATCTCTGCTGGATTTA CGTATCTGAACCCATCATCTTCCCATTCGATGGATGAAGGAAAAGTGTCTTCTAT ATTTTACACCATCATTTGTTCCCATGCTCAACCCCTGATTTACAGTCTTAGGAAT AAGGACGTGAAAAATTGCTCTGAAGAAAATGATTGAATGAAGATAATTCTTCTGA TAA	NMEKGNQSTVNKFELSG LTEQPELQLPLFLFLGIY LLTVLGNLGMILILLSSY LHTPMYFFLSSLSFIDFCQ STVITPKMLVKFVREKNE ISYPECITQLCFFVIFAVSE SYMLAAMAYDRYVAICS PLLYSSIMSQHKCLSLVL GVVILGIVCASAHVGCIFR IDFKSDLINHYFCDLISIL NLSCSNIFVNDLVILFSLI NTIPTLTILSSYAFIISILR IKSTEGRSKAFSTCSSHS AVAIFYISAGFTYLNPS HSMDEGKVSSIFYTIIVPM LNPLIYSLRNKDVVKIALK KMIE

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_G	99/100	AAATTACTATTATGAATCATCTTCAGTGACTGATTTTATCCTCGAAGGACTAAC AAAACGCCAGAGCTTCAGCTCCACTGTTCCTCTTGTCTTCTGGGCATACATGTG ATTACAGTGTGGGAAACTTGGGCATGATCCTCTTAATCAACATTAGTTCTCAAC TTCACCTCCAAATGTATTATTTTCTCAGTCACTTATCCTTCAATTGACCTCTGCTAT TCCTCTGTCATTACACCAAGATGTTGGTGAACTTTGTATGTGCAAAAGAACACAA TCTCCTTTAAGGAGTGATGACTCAGCTTATTCTTCTCCTCTTTAGCTATTTCA GAAGGCTACCTGCTGACAGCCATGGCCTATGACCGCTATGTTGCCATCTGTAGCC CACTGCTTTATAACACTGTAATGTCCCAAGTCTGTCCATCAATGATGGCTGT GGTATACCTCACTGGGCTTCTTGGGGCTACTGTCCATACAAACCGTATGACAATG TTGTCTCTGTGGGTCTCATATTATCAGGCATATTTTGTGATATTCTACCTTT GTTGACTCTGTCTTGTCAAGTACCCATATCAACGAAGTACTGCTGTTATTATT GGTGGAGTTAATACCTAGCACTACACTGGCTGTCATCATCTCTTATGCTTTCA TTCTAACAAAGCATCTTCGCATCCGCTCCCAATGAAGACGTTCCAAAGCATTGG CACCTGTAGCTCCCACTTCCAGTAATAATATGGAACAAGAGAGGTGCTCTCT ATGTATTTCAAGCCACCTTCCAGTAATAATATGGAACAAGAGAGGTGCTCTCT GTGTTCTACACCAAGTATCCCAATGCTAAATCCCTCATATACAGTCTGAGGA ACAAAGGATGTAAAGACTGCTCTGAAAAGAGATGGTTGGTAGAAGGCAGTTATCCT GACAAATTGA	MNHSSVTDFEILEGLTKRP ELQLPLFLFLGHIHVTIV GNLGMILLINISSQLHSPM YYFLSHLSFIDLCSVITP KMLVNFVCAKNITISFKEC MTQLYFFLLLAISEGYLLT AMAYDRYVAICSPLLYNT VMSHKVCSIMMAVVYSL GFFGATVHTTRMTMLSF CGSHIRHYFCDILPLLTL CSSTHINEVLLFIHGGVNT LAPTLAVIISYAFILTSILRI RSNEGRSKAFGTCSSHIM AVGIFFGSITFMYFKPPSS NNMEQEKVSSVFYTTVIP MLNPLIYSLRNKDVKTAL KKMVGRRQLS

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_F	101/102	ACAATGGAAGAAAATCAATGATACCTCAGTGGCTGAGTTCACTCCTCACTGGGTTA ACAGAGAACCCAGAGCTCCAAATTGCCCTCTATTCTTATCTTCTAGCTGATATATT TGGTTACAGTTGTTGGAAACCTTGGCATGATTGATTGATTCTGATTAGTTCTCA GCTACATACACCCATGTTATTATTTACTCAGGAGCCTGTCTTTATTGACTGTTGT CAATCCACTGTCATTATTCACCAAAATGCTGTTGAACCTTGTGACAGAGATGAATA TCATCTCATACCCCAATGCATAGCTCAGTTCTACTTCTCTGTGCTTTTGTCTGTT TCAGAAATGTCACATGTTGGCTGCAATGGCATATGACCGCTATGTGGCTATATCTA ATCCTTTGCTTTATAATGTAACCATGTCCTATCAAGTCTGTTGTTGATGGTAGC TGTGGTGTATGGTATTGGCTTAATCAGTGCCACAGCTCACACAGCTTTCCTACTA AGAGTGCTTTTGTAAAGTCTGATATAATAAACCACTACTTCTGTGATCTTTTCC CATTACTGGAGCTCTCGTGTCTAGTACTTATTAATGAAGTTCTAGCACTCTC CTTCAAGTGCAATTAATAATTATGTACCACTCTGACCATCTTAGCTCTTACATCT TCATCATTTGTCAGTGTCTCCACATTCAATCCACTGGAGGAGTCAAGGCCCTT TCGCACCTGTCAGCTCCACATCATGCTGTTGCAATATTTTGGTTCTACAGTA TTCATGTATCTACAGCCATCTTCAGTCACTGACCTCCATGGACCAAGGAAAGTATCAT CAGTGTTTTATACCATTTGTTGTCCTATGTTGAATCCTCTGATCTACAGCCTGAG AAATAAAGATGTCAGAGTTTCCCTTAAAAAGTTACTACAAAAAGATAAGTTTCTC AAAACAAAAAATTAGATTACCTTGGCAATAGATTATAGCATATAACTTTACAATT AGGG	MEEINDTSVAEFILTLTE NPELQLPLFLFLAVYLV VVGNLGMIVLILISSQLHT PMYYLLRLSLSFIDCCQST VIIPKMLLNLFVTEMNIISY PQCIAQFYFFCAFAVSEC HMLAAMAYDRYVAISNP LLYNV/TMSYQVCSLMVA VVYIGLISATAHTVFLR VLFCKSDIINHYYFCDLPL LELSCSSTYINEVLALSFS AFNIIPALTLSSYIFIIVS VLHIQSTGGRVKAFRTCS SHIMAVAIFFGSTVFMYL QPSSVSSMDQKQVSSVFY TIVVPMNLNPLIYSLRNKD VRVSLKKLLQKISFLKTK N

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_E	103/104	AATGGGCACTGGGAATCATTTCTGTAAACAGTTGTGTGTTGCTTGGTGGGATTAAACA CAGCAGCCTGAACCTCCTGCTGCCCTCTTCACTTCTGTTCTCTGGGCATCTATGTGG TGACAGCAGTGGGAACCTGGGCATGATCCTGCTCATCACAGTCAGTCCACTGC TGCATACTCCTATGTACTATTCTCCTCAGCAGCTTATCCTGTGTTGATCTCTGCTAT TCCACTGTCAATTACACCCAAATGCTGGTGAACCTTCTTGGGAAGAAAAATTTGA TTGTCTACTCAGAGTGCACTGCCATGGCATATGATCGCTATGTGCCCATCTGTAGA GAGGCTACCTGCTGACTGCCATGGCATATGATCGCTATGTGCCCATCTGTGG CCATTGCTGTATAATGTGATCATGTCCTCCAGACTTTGCTCACTAGTGTGG TTGCTTTCATCTTAGGCTTTGTTCTGCCTTAGCACACACAAAGTCTATGATGAA TCTGAGCTTCTGTAAATCCCACGTCATAAGCCATTATTCTGTGATGTTCTTCCCC TCCTAAACCTCCTCCTCTGTACATAAAGCTGAATGAGCTTCTTCTATTCATCAT TGCAGGCTTCAACACCTTGGTGCCCACTAGCTGTGGCATCTCTTATGTCTTT ATTTTCTGCAGCATCCTTCACATCAAGTCATCAAGGCAGGTCCAAAGCCTTTG GAACCTGCAGCTCTCATCTCATGGCTGTGGGATCTTCTTTGGGTCTATCACCTT CATGTATTTCAAGCCTCCTTCAAGTAACCTCTCTGAGAGCAAGAGAGGTGTCTTCT GTGTTCTATACACAGTGATCCCCATGCTGAACCCATTATATACAGTTTGTAGGA ACAAAGATGTGAAGAAAGCATTTGGGCAAAATGTCTGGCAGGGAGATAA	MGTGNHSVTVVFLVGL TQPELLLPFILFLGIYV VTAVGNLGMILLITVSPLL HTPMYYFLSSLSCVDLCY STVITPKMLVNFLGKKNL IVYSECMAQLFFVIFVVA EGYLLTAMAYDRYVAIC RPLL YNVIMSSRLCSLLVL VAFILGFVSALAHTSAMM NLSFCKSHVISHYFCDVLP LLNLSCSDIKLNELLFIIA GFNTLVPTLA VAISYVFIF CSILHIKSSKGRSKAFGTC SSHLMAVGIFFGSITFMYF KPPSSNSLEQEKVSSVFYT TVIPMLNPLIYSLRNKDV KKALGKCLAGR

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_D	105/106	TAATGGCCACTGGGAATCATCTCTGCAGCAGTTGTGTTTGGTGGGATTAAAC ACAGCAGCCTGAGCTCCTGCTGCCCTCTTCATCTGTTCTCTGGGCATCTATGTG GTGACAGCAGTGGGAACCTGGGCATGATCCTGCTCATCACAGTCAGCCCCACTG CTGCATACTCCCATGTACTATTCTCTCAGCAGCTTATCCTTTGTTGATCTCTCCTA TTCCACTGTCAATTACACCCAAAATGCTGGTGAACTTTCTTGGGAAGAAAAATTTC ATCACTTATTCGGAGTGCATGGCTCAGTCTTTCTTTGCGGCTTTTGGTGCAC TGAGGGTTACCTCCTGACTGTTATGGCGTATGATCACTACGTGGCCATCTGCAGA CCATTGCTGTATAATGTGATGATGTCCTCTAACACTGCTTACTGTAGTCTAG TTGCCTTCACTAGCCCTTTTCTGCTGTAGTACACACAAGTCTATGATGAG TCTGAACTTCTGTAAAACCTACATCATAAAGTCAATCTCTGTGATGCTCTTCCTC TCCTCAAACTTCTGCTTAACACACATCTCAATGAGCTTCTCATATTATTATT GGAGGATCAACACCTTGGTGCCCACTTGTGCTGTTGCCATTTCTATGTCTTCA TCTTCTGCAGCATCCGTCACATCAAGTCAATCAAGAGCAGGTCCAAGCCTTTGG AACCTGCAGCTCTCATCTCATGGCTGTGGGATCTTCTTTGGGTCTATCACTTTC ATGTATTTAAAGCCTTCTTCAAGTAACTCTCTGGAGCAAGAGAGGTGTCTTCTG TGTCTACACCCACAGTATCCCCATGCTGAACCCATTAAATATACAGTTTGAGGAA CAAGATGTGAAGAAAGCACTGGGCAGATTCTCTGTAAAGAGATAA	MATGNHSAAVFVLVGL TQPELLLPFLFLGIYV VTAVGNLGMILLITVSPLL HTPMYYFLSSLSFVDLSY STVITPKMLVNFLGKKNF ITYSECMAQFFFAVFVV TEGYLLTVMAYDHYVAI CRPLLNVNMMSSKHCLL LVLVAFTLGLFSAVVHTS AMMSLNFCITYIISHYFC DALPLLKSCSNTHLNEL LIFIIGINTLVPTLAVAIS YVFIFCSIRHIKSSKSRKA FGTCSHLMVAVGIFFGSIT FMYLKPSSSNSLEQEKVS SVFYTTVIPMLNPLIYSLR NKDVKKALGRFSVRR

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_C	107/108	GGAAATTGAACATAGCATATGGCAACAGAGAACTATTGCATGTTACCTGAGTTCA TTCTGACTGGGCTCTCAAAGAACCCACAACTCCAGATGCCCTCTCTTCCCTCCTT CCTAGGAATCTATGTGTCACCTGTAAGTGGGAATTTGGGCATGATTACACTGATT AAGCTCAGTTCTCACCTGCATACCCCATGTAATTTCCCTCAGTAGTTTGTCCCTT TATTGATCTCTGCCATTCCACTGTCAATTACCCCAAAATGTTGGTGAACCTTTGTG ATAGAGAAAAACATCATTTCTTACACTGATGCATGGCTCAGCTCTATTCTCTTC TAATTTTGTCTATTGCAGAGTGCATATGTTAGCTGCAATGGCATATGATCGCTA TGTTGCCATCTGTAACCCCTTGCTTACAATGTAACCATGTCCTATCAGATTAC ACTTCCCTGATCTTTGGAGTCTATATTGTTGGTGGTTTGTGCATCAGCTCACA CAGGCTTCATGATCAGAAATACAGTTTGTAACTTAGAGGTGATCAACCACTATT CTGTGATCTTCTCCCTGCTGGAGCTTGCTCACTTAGTACTTATGTTAATGAAT TGTTAGTTTATGTTTGGTACATTTAACATTGTTGTTCCAACTTACTGGAGGCA ACTTCTTACATCTTCATCATTTGCCAACATCTTACGATTCGTTCTACTGGAGGCA GGTCCAAAGCCTTCAGTACCTGCAGCTCCACATCTTAGCTGTTGCTGTGTTCTT TGGGTCTGCTGCATTCAATGTACCTTCAACCATCATCAGTCAGCTCCATGGACCAA GGGAAAGTGTCTGTGTTTATACCATTTGTTGTTCCCATGCTGAACCCCTTGA TCTATAGTCTGAGGAATAAGGATGTCAGTGTGCCCTGAAGAAAATACTAGAAA GAAAATTATTTCATGTAAACTGAA	MATGNYCMLPEFILTGLS KKPQLQMPLFLLGLIYV VTVVGNLGMITLIKLSH LHTPMYYFLSSLSFIDLCH STVITPKMLVNFVIEKNIIS YTGCMAYQLYFFLIFALAE CHMLAAMAYDRYVAICN PLLYNVMTMSYQIYTSLIFG VYHGVVCSAHTGFMIRI QFCNLEVINHYFCDLLPL LELAHSSTYVNELLVLCF GTFNIVVPTMTILTSYIFI ANILRIRSTGGRSKAFSTC SSHILAVAVFFGSAAFMY LQPSSVSSMDQKVVSSVF YTIVVPMNLNPLIYSLRNK DVSVALKKILERKLFM

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073947_A	109/110	CTATGCGGAATTTCTCAGTTGTGACTCAATTTATCCTTCTGGGCATCCCTCATAC AGAGGGTGTGGAGATCATGCTCTTTGTCTCTGTTTGTCTTTCTACATCTTCACCT TAGTGGGGAACCTTGCTCATACTTTTGGCGATTGTCTCCCTCCAGTCGGCTTCACAC TCCCATGTACTTCTTCTCTGTCGACAGCTGTCAAGTGTGTGATATATTTTTCCTCCG TTAGCTCTCCCAAGATGCTGTTCTACCTCTCAGGAATAGCAGAGCCATCTCCTA TACAGGCTGTGTTTGGCAGCTCTTCTCTACCATTTCTTGGCTGTACTGAATGTT TCCTATACACAGTGTGGCTTATGACCGCTTATGCCCATATGCTTCCCTCTAAG GTACTCAATAATCATGAACCAAAAGTGTGTCATCATGCTGTGGGACATC ATTTTGTGGCTGCTCAGGCTACTTTCTGACCACTCAACCTCCAGTTGCCCT ATTGTTGGTCCCAATGAAGTGGATTATTCTTCTGTGATATCCCTGTATGCTGAA GCTGGCTTGTGCAGACACATCAACCTAGAGATGGTGGTCTCATCAGTGTGGG GCTGATGCCCTCAGCTGCTTCTCTCTCATTCTCAGCTTACAGCTTCTCATCCTT GCTCCATTCTTCAGATCCGCTCTACTAGGGCCGGCATAGAGCTTCTCTACCTG CAGTGCCCATCTCAGTCCCATTTCTCTGGCTTCAAGCCAGTAGTCTCATATAC CTCCAGCCTACTCCCAATCCCTGGCTTAAATGCAGCAGTTCAGTCTTGAATAACC TGGTGACACCTATGCTGAATCCCTTGTGATCTATAGCCTAAGGAATAAGGAAAGTAA AATGTTCTCTAAAGAAATGCTACAGCAAGGGCCTATTCTGTCTAAAGAGTAT AAAGGCTTAGATTCTAATACTTTAATACTATACTTCTTCAAAAACCTTTCCTTTC T	MRNFSVVVTQFILLGIPHTE GVEIMLFVLFLSFYIFTLV GNLLILFAIVSSRLHTPM YFFLCQLSVCDIFFPSVSS PKMLFYLSGNSRAISYTG CVCQLFFYHFLGCTECFL YTVMAAYDRFIAICFPLRY SIIMNHKVCAIMAVGTSF FGCIQATFLTTLTFQLPYC GPNEVDYFCDIPVMLKL ACADTSTLEMVGLISVGL MPLSCFLLILTSYSFILCSI LQIRSTEGRHRAFSTCSAH LTAILLAFMPVVLIYLQPT PNPWLNAAVQVLNNLVT PMLNPLIYSLRNKEVKCS LKKMLQQGPILSKK

Table 1

Acc. No.	SEQ ID NO (NucI) / SEQ ID NO (PstI)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073945_D	1111/112	GACATGACATCAGGAAACAACTGCACAGTGTCTGAATCTTCTGGCTGGGCTCT CAGAGGAGCCAGAACTCCAGTCCACTCTTCTGCTCTTCACAGGAATATATCT AATCACTGTGGTAGGAACCTGGGCATGATCACACTGATTGGGATCAGTTCCCA CCTGCACACAGCCATGTACTTTTCTCAGCAGTCTCTCCTTCATTGACTTCTGTCT AGTCCACAGTTGTACCCCTAAATGCTGGTGAGCTTCTGACGGAGAAGAACA TCATCTCTACCTTGGATGCATGGCTCAGCTCTACTTCTTCATCATTTTGGGGCT GCAGAGTGCTACACATTAGCTGCAATGGCATATGACCGCTATGTTGCCATCTGTA ACCTTTACTTTACACTGTAGTCATGCTCTATCAGGTTTACAGTTCCTTGATTCA GGAGTGATATTTATGCTGTGTTCTGTGCATCAACCACTATTCTGTGATATTCTTCC GGATTCAAGTTTGGCAAATTAGATGTGATCAACCACTATTCTGTGATATTCTTCT CCTCTTGAAGCTTGCAATCTTTGCTCCAAACATTGATCAATTACTTCTACATCTTC TTGGTACACTGAATATCTTTGCTCCAAACATTGATCAATTACTTCTACATCTTC ATTATTGCAAGCATCTTCCACATCTGCTGTTGCCATTTTCTATGTTCTGCTGCAATC GCACCTGCAGTTTCACACATCTCTGCTGTTGCCATTTTCTATGTTCTGCTGCAATC ATGTACTTACAACCATCACGAGTGAATTCGATGGACCAAGGAAAGTGTCTCTCT GTGTTTACACTACTGTGTGACCCATGCTGAACCCCTTGATCTACAGCCCTAAGGA ATAAGGATGTACAGTTGCACCTGAAGAAATACTTGAAGAAAGAAATTTTCATGT GGTCAGAAAGTCACATAAATAATATTCTTAGAGGAAA	MTSGNNCVTSEFFLAGLS EEPELQLPLFLFTGIYLI VVGNLGMITLIGISSHLHT AMYFFLSSLSFIDFCQSTV VTPKMLVSFLTEKNIISYL GCMAQLYFFHFGAAECY TLAAMAYDRYVVAICNPL LYTVVMSYQVYSSLSIGV YIYAVFCASVHTGVLTRI QFCKLDVINHYFCDILPLL KLACSNYIDEMLILFFGT LNIFAPTLIITSYIFIASIF HIRSREGRSKAFSTCSSHI SAVAIFYGSAAFMYLQPS RVNSMDQKGVSSEVYFTT VVPMLNPLIYSLRNKDV VALKKILERKNFMWSEV T

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073945_C	113/114	GACATGGCAGCCGGAACCACTGCACAGTGACTGAGTTCTTCTTAGTTGGGCTC TCAGAGAAAGCCAGAAATCCAGCTGCCCTCTTCTCCTCTTCTTGGAAATCTATC TAATCACTGTGACAGGAAACGTGGGCATGATCACACTGATTGGGCTTAGTTCCCTC ACCTGCACACCCCATGTACTTTTCGTCAAGGAGTCTGCTTCAATTGACTTCTGTG CAGTCCACAGTTGTTATTCCTAAATGCTCATGAGCTTCTTCTTCTCATATTTGGTATT TCATTTCTACTCTGGATGCATGTTTCACTCTACTTCTTCTTCTCATATTTGGTATT GCAGAGTGCTACACGTTAGCTGCAATGGCCTATGACCGATATGTTGCTATTGTA ACCCCTTGCTTTATAATGTAACCATGTCCTATCAGATTACAATCTCTGATTTCG GGGTCATATATTTTGGTGTGCTGTTTCATCCTTAATCACTGGCTTCATGTTTAG GATTCAGTTCTGTAATTAGATGTGATTAAACCACTATTTCTGTGATCTTCTCCCTC TCTTGAATCTTGCACTCCTTAATATCTATATCAATGAAATATTGATTCTAGTTATT GCTACACTGAATGTCTTTATCCAGTGATGACCAATTAATCTCTACATCTTTCAT TATTGCCACCAATCTCTACATTCACCTCCAGTGAGGCAAGTTCAAAGGGTTTAGT ACTTGTAGTACCCACATCTCTGCTGTGCTATCTTTTATGGTTTCAGGAGCAATCA CATACTTACAGCCCTCATTAATCTGAAATCTATGGCCAAAGCAAAAGTGTCTCTGT GTTTGTACTACAGTTGTACCCATGCTGAACCCCTTCATCTACAGCCTGAGGAAAT AAGGATGTCAGTTTTCACCTGAAAAAATAATTGAAAGAAAAAATTCATGTAA GCAGAAATCAT	MAAGNHCTVTEFFLVGL SEKPEFQLPLFLFLGLYLI TVTGNVGMITLIGLSSH HTPMYFFVRSLSFIDFCQS TVVIPKMLMSFLTEKNIIS YSGCMVQLYFFFIIFGIAEC YTLAAMAYDRYVAICNP LLYNNVTMSYQIYNSLISGS YIFAVVCSSLITGFEMFRIQ FCNLDVINHYFODLLPL NLASSNIYNEILILVIATL NVFIPVMTIITSYFIATIL YIHSSEKFKGFSTCSTHI SAVAIFYGSGAFTYLPQSL LNSMGQAKVSSVFCTTV VPMLNPFYSLRNKDVSF ALKKIFERKKFM

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073945_B	115/116	ATTTGAATGGAGGACATGGCAGCAGGAACCACTGCACAGTGACTGAGTTCCTC TTAGCTGGCTCTCAGAGAGCCAGAACTCCAGCTGCCACTCTTCTGCTCTTCA CAGGAATCTATCTGATCACCATGGCAGGGAACCTGGGCATGATCACACTGATTG GGCTCAGTTCTCATCTGCACACACCCATGTACTATTTCTCAGCAGTCTGTCTCT CATTGACTTCTGTCAGTCTACAGTTGTCAATCTTAAATGCTCGTGAGCTTTCTG ACAGAGATGAACATCATTTCTACTCTGAATGCTGCTCAGCTCTACTCTCTCC TCACCTTTGGTATTGCAGAGTGCTACACATTAGCTGCAATGGCCTATGACCGATA TGTGCTATTGTAAACCCCTTGCTTACAATGTAAACCATGCTCTATCAGATTACA GTTCTCTGATTTTCAGGGGTATATATTTTGTGTGATCTGTTCATCCTTTAACACT GGCTTCAATGCTTAGGACTCAGTCTGCAATTTAGATGTGATTAAACCACTATTCT GTGATCTCTTCCCTCTTGAATCTTGCACTCTCTAATACCTACATCAATGAAATA TTGATTCTATTTTTGTCTACACTGAATTCATTTGTCCAGTGTGACCACTATTAC TTCCTACATCTTCATTATTGTACCATCTCTCTCCATTCACTCCAGGAGGGCAAG TTCAAAGCTTTTAGTACTTTGTAGTACCCACATCTCTGTCTGTTGCTATCTTCTATGG TTCAGGTGCATTCACGATTTTACAGCCCTCATCACTGAATTCATGGGCCAAGCA AAAGTGCTCTGTGTTTTATACTACTGTGTGACCCATGCTGAACCCCTTGATCT ACAGCCTGAGGAATAAGGATGTCAGTATTGCACTGAAAAAAATACTTGAAAGAA AAAAAATTCATGTAAAGCAGAAATCAT	MEDMAAGNHCTVTEFFL AGLSEKPELQLPLFLFTG IYLITMAGNLGMITLIGLS SHLHTPMYYFLSSLSFIDF CQSTVVIPKMLVSFLTEM NIISYSECMAQLYFFLTFG IAECYTLAAMAYDRYVAI CNPLLYNVMTMSYQIYSSLI SGVYIFAVICSSFNTGFML RTQFCNLDVINHYFCDLL PLLNLASSNTYINEILIFF ATLSFVPVLTITTSYIFIIV TILSIHSREGKFKAFSTCS THISA VAIYFGSGAFTYLO PSSLNSMGQAKVSSVFYT TVVPMNLNPLIYSLRNKDV SIALKKILERKKFM

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC073945_A	117/118	AACATGGCAGCTGCAAAACCAATTGCATAGTAGTACTGAGTTCCTCTGGCTGGACTCT CAGAGAAATCAAAAAGTTTCAGCTGCCCTTTTCTCCCTATTGTAGCAATCTATCT GATCACTGTGGCAGGAAACCTGGGGATGATTGCATTGATTGGGATCAGTTCCCA CTTGACACACCCATGTACTATTCTCAGCAGTCTGTCTTCATTGACTTCTGTCT AGTCTACAGTTGTTACCCCTAAAATGTTGGTGAGCCTCTGACAAAAGAAACA TCATCTCTACTCTGGATGCATGTTTCAGCTCTACTTCTTCATCAGTTTGGAACT GCAGAGTGTACACATTAGCTGTAATGGCATATGACCGCTATGTGCCATTGTGA ACCCCTACGTTACAATGTAACCATGTCTTGTGATCAGTAAACACCCGCTTTATAATT AGGGGTGTATATTATGCTGTGTTCTGTGCATCAGTAAACACCCGCTTTATAATT AGGATTCAGTTCTGCAAGTTAAATGTGATCAACCACTATTTCTGTGATCTTCTTC CCCTGTTGAAACTTGCAATGCTCTAAATACCTATATCAATGAAATATTGATCTATT TTTTGGTTCAGTAAACAATCTGTGTCCCAATGCTGACTGTTATTACTTCTACATCT TCATCATTTGCCAGCATCTCCGTAATTCGCTCCAGTGAGGCAAGTTCAAAGCCTT CAGTACTTGCAGTTCCACATCTCTGCTGTGCTATCTTGTATGTTCTACTGCAT TCACATACTTACAGCCTTCATCAGTGAGTTTGGTGGACCAAGGGAAGTGTCTCTC TGTGTTTTTATACTACTGTTGTACCTATGCTGAACCCATTGATCTACAGCTTGAGG AATAAGGATGTCACTCTTGCAATTGAAAAGAAATCTTGAACAAAAGAGGCTTTAT GTAAGCAGAAGTCGTGTGAAGATTATTAAATTACTAACATATTATTGCTTTACTCC TTCAGGATAAGAAATGGAGGACATGACAGCAGGAAACCAATTGCACA	MAAANHCVTEFFLAGLS ENQKVQLPLFLFLVAYLI TVAGNLGMIALIGISSHLH TPMYYFLSSLSFIDFCQST VVTPKMLVSLLTCKNIIS YSGCMVQLYFFISFGTAE CYTLAVMAYDRYVAICN PLRYNVMTSYQIYSSLISG VYIYAVFCASVNTGFIIRI QFCKLNVINHIFCDLLPL LKLACSNITYINEILILFFGS VNICVPMLTVITSYIFIASI LRIRSEGEKFAFSTCSSHI SAVAILYGSTAFYTLQPSS VSLVDQGVSSVFYTTV VPMNLPLIYSLRNKDVTL ALKRILEQKRLYVRSRV KIINY

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC074177_C	119/120	CTGATTTCATCCATAAAACATGACAAACCCACACTGTTGGTGACAGAAATTCACCTTGCT GGGCATCCCTGAGACAGAGGCCTGGAATATGCCCTGCTTTTCTGTTTCAACA ATGATGCTGCTGCCCTGCTGGGAACTTTCTCTCAATCTTACTGCAATCACTACCT CCCCAAGACTACACACACCCCATGTACTTTTCTTGGGAAACCTCTCCATCTTTGA CTTAGGTTTCTGTTCCACTACAGCTCCAAGATGTTGTCTATATCTCTCAGGATGG GGTGAGGGATCTCTTTACAGGATGTTGTACAAACACTTCTTCTATCATTTGTC TGGGTTGCACATTTGTTCTTGTACACAGTATGAGCCATGACCCGCTTTGTTGC CATATGCTTCCCTTTGAGATACACAAATCATGAAACACAGAGTATGCTGTGTC TTGGCCACAGGGACCTGGATGAGTGGCTGTGTCATGCCACCATCCTAACTTCCC TCACCTTCCAGTTGCCCTACTGTGGCCCTGAGGAGTATCTTCTAGCAGAGGTA CATGCTGCAGTGTACTGCTAGCCTGTGAAGATTCCTCTAGCACAGAGGTA GGTTTCACAAATGTTGGTCTTTATCTCTCAATTTGTTTCTTCTCATTTATGTC CTACACTCGAATGGGATCTCCATCTCAAAATCCGCTCAACAGAGGAGGCA GAGAGCTTCTCCACCTGCAGTGCCCACTCAGCCATCATGTGTCTATGGA CCTGTCACTGTCTACCTACAGCCCACTCAGTCCATTTGCTTAGTGCATTGA TTCAGATTTTGCACAAATCTTGTGACACCCACCATCAACCCATTGATCTACAGCCT GAGGAACAAGGATGTGAAAGCAGCCCTGAGGCATGTATTTCTTAAGAGGTGCTCT TAGCCTGGAAGTAAATGAAACACAGCTAAGT	MTNHTMVTEFTLLGIPET EGLLENALLFLFSTMAYACA LLGNFLILTAITTSPLRHTP MYFFLGNLSIFDLGFCSTT APKMLSYLSGWGGGGSFQ GCVVQHFFYHCLGCTLCF LYTTVMAYDRFVAICFPLR YTIIMNHRVCCVLAATGT WMSGCVHATIL.TSL.TFQL PYCGPSEVSYFFCDMPAV LLLACEDSSLAQRVGFNT VGLLSLICFELIVSYTRIGI SISKIRSTEGRQRAFSTCS AHLTAIMCVYGPVIVYL QPNPSLLSAIIQLHNLVT PTINPLIYSLRNKDVKAAL RHVFLKRCLSLEVNENS

Table 1

Acc. No.	SEQ ID NO (Nucl) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068905_B	121/122	AATGGCTGTAGGAAATTCTCTCTCAGTGAAAGAATTATTTCTGCTGGGCTTGACA CAAGAGCCAGAGCTCCAGCTGCCGCTCTTCTCTCTCTTGGGAATCTATGTGG TCTCTGTGATGGGGAACCTGGGCTTGATTGTTCTGATTGTGTGAATCCTCCCT GCACACCCCATGTACTACTTTCTCTTCAACCTTCTCTCACAGATCTCTGCTACT CCACTGTCTATAACCCCAAGATGCTGGTGGGTTTGTGAAGCAGAACACCATCTC TCATGCAGAGTGTATGACTCAGCTTTTCTCTCTCTCTCTTCTTGTATTTGATGAAT GCTACATTTTGACAGCAATGGCCTATGACAGATATGCTGCCATCTGTAAAGCCCT GCTTTACCAGGTCACCATGTCCCATCAGGCTGCTCTTGATGACAGTGGGGATG TATGTGATGGGCTTGTGGTGCCATAGCCACATTTGTGCTGCTGAGACTCA CCTTCTGTGAAGGCCACATAATTAATCATACTACATGCTGTGACATACCCCTCTCCT GAAGCTCTCTGCACAAAGTACCTACATCAATGAGCTGGTAGTTTTCATTGTTGTG GGTGTCAATGTGATAGTTCTACATTGACTATTTTATTACTTATACCTTAATCCT TTCCAACATCCTCAGCATCCATTCTGCAGAAAGTAGATCAAAAGCCTTCAGTACC TGTGGCTCCCATGTGATAGCTGTTTCTCTTTCTTTGGAGCTGCAGCCTTCATGTA TCTTAAGCCTTCTAGTGCACTCTGTGGATGAAGAGAAATTATCAACCATTTTAT ACCATTTGTGGGCCCAATGTTGAATCCTTTTCATCTATAGCATAAAGGAATAAGGATG TTCACATTGCACTGAGAAAAAATTTGAAGAAAAAGTATGTTTACTTAAATAGAAAT CT	MAVGNSSSVKEFILLGLT QPELQLPLFFFLGIYVV SVMGNLGLIVLIVLNPPL HTPMYYFLFNLSTDLCT STVITPRMLVGFVKQNTIS HAECMTQLFFCFVDE CYILTAMAYDRYAAICKP LLYQV/TMSHQVCLLMTV GMYVMGLVGAIAHIVCM LRLTFCEGHINHYMCDIP PLLKLSCTSTYINELVVF VVGVNVIPTLTIFITYTLI LSNILSIHSAEGRSKAFST CGSHVIAVSLFFGAAAFM YLPSSASVDEEKLSTIFY TIVGPMLNPFYISIRNKDV HIALRKTLKKSMTF

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068905_C	123/124	AATATTTTGAATGGAGAATGACTCTTCTGTGACTGAGTTGTTTTATGGGATT AACAGAACCAACCTGAGTTACGGCTGCCTTGTGTTTTTGTGTTCTGCTGAATTAT ACAGCTACCGTGATGGGAAATTGAGCTTAATGGTTCTTATTTGTCTGAATTCAC ACCTTCACAACCCCATGTACITTTTCTTGTTCAAATTTATCCTTGGTTGATTTCTGT TATTCATTTGTTGTACCCCTAAATGCTAATGGGTTTTGTTTCTGAAAAAGCA TCATATCTTATACAGGATGCATGACTGACTATTCCTTTTCTGCTTTTGTGTTAAT TCTGAGTGTATGTGCTGACAGCAATGGCCTATGATCGTTATGTGGCCATCTGTA AGCCATTGGTATATGCCATCCTTATGTCTCCTCGGATGTGTTCCCTGCTAAATGAT TGGGTCCTACTTAATGGGATTTGCAAGTGCCATGGCTCATACTGGCTGCATGATT AGGCTCAAGTTTGTGATTGCAACATCATCAACCATTACATGTGTGAAATATTC CCCTGCTCCAGCTCCTGTCAGTAGTACCTATGCCAATGAACCTTGAGCTCTCT TATTGCTGTATAGTTGTCATTGTATCTGGTCTGTATCTTAATGTTCATATGCTT CCATCCTCTTAAATGTTTTCAGATGTCATCAGCTACAGGTGGTCCAAAGCCAT GGGTACTTGTGGTCCCATATCATAACTGTTAGTCTATTCTATGGTTCTGGACTG CTTACTTATGTCAAACCAAGCATCCGCTGAATCTGTAGATCAGGGGAAATTTTCT CAGTGTTTTATACCTTTATGGTTCCCATGCTGAATCCTCTTATTACAGTCTCAGG AACAAAGGATGTCAAATAATCTAATGTTACTATTTTACTATTCTCCTCCTAGACAT GAT	MENDSSVTEFVEMGLTE QPELRPLFFVFLNLTAT VMGNLSLMVLICLNSHLH NPMYFFLFNLVSLVDFCYS FVCTPKMLMGFVSEKSIIS YTGCMTQLFFFCFFVNSE CYVLTAMAYDRYVAICK PLVYAILMSPRMCSLLMI GSYLMGFASAMAHTGCM IRLKFCDSNIINHVMCEIF PLLQLSCSSTYANELVSSL IACIVVIVSGLVILMSYASI LLNVVQMSSATGWSKAM GTCGSHIITVSLFYGSGLL TYVKPASAESVDQKFFS VFYTLMPMLNPLIYSLR NKDVKYSNVITFTILT

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068910_B	125/126	AATGGCTCCAAGAAATAGCTCTGTGACTGAATTTATCCTTGTGGGATTTTCA AACCAACGAGCTCTCCAGCTGCCTCTCTTCGTCCTTCTTAGGTATCTATGTGCT GACTGTTATAGGCAATTTGGGACTGATCACCTTAATTTGGTTGAATTCAGTCTTT CATACTCCAATGTACTTTTTCCTCTTCAACTTGTCTTATAGATTCTGTTATTC CTGTGTGTTCAAGCAAAATGTTGAGTGATTTTGTCTCAGAAAAACATTATCTCC TACATGGGATGCACTCAAACTGTTTCTTCTGTTCTTGTCAATTCTGAATG CTACGTGCTGGTGCAATGGCCTATGATCGCTATGTGGCCATTGCAATCCTCTG CTGTACACAGTTACCATGCTCTCCTCAGGCTGCACTCTGCTGATGTTTGTTCAT ATGTGATAGGGTTTGTCTGGAGCCATGGCCCATATCTCTGTGAAGTTCTTCCCTTTA CTTCTGTGATTCCAAATATGATCCACCAATTATCTCTGTGAAGTTCTTCCCTTTA CAGCTCTCTGACCAAGTACCTATGCCAAGAGCTTGTGTTTCTTATGTTGTTG GAGTAGTCAATCAGCATCCAGCATCAGCATCTTATCTCTTATGCAATTGATTCT CTCCAACATTTCTTAAGATTCTTCTGCTGAAGTAGATCCAAAGCCTTTGGCACA TGTGGTTCCCATGTAGTTGCTGTTGCTCTGTTTGTGGTCAAGGGGCAATTCACCT ATTTAACAAACCTCTTCCCTGGTTCAATGGAAGAGGGAAAGTTGCTTCAGTATT TTATACCAATGTGGTTCCCATGCTTAACCCACTGATCTATAGTTTGAGGAATAAA GACGTTAAACTTGCCCTAAATAAACCTTGAAGAGAGTGCTCTTCTGTATGA	MAPRNSSSVTEFLVGFPSN QPALQLPLFFVFLGIYVLT VIGNLGLITLIGLNSSLHT PMYFFLFNLSFIDFCYSCV FTPKMLSDFVSENIISYMG CMTQLFFFCFFVNSECYV LVSMAYDRYVAICNPLLY TVTMSPPQVCTLLMFCSY VIGFAGAMAHTGSMILT TFCDNMIHHYLCEVLPL LQLSCTSTYANELVFFIVV GVVITASSISIFISYALILSN ILKIPSAEGRSKAFGTCSG HVVAVALFFGGGAFYLT TSFPGSMEEGRFASVFYT NVVPMNLNPLIYSLRNKDV KLALNKTLLKRVLF

Table 1

Acc. No.	SEQ ID NO (Nuc) / SEQ ID NO (Prot)	DNA SEQUENCE	PROTEIN SEQUENCE
GMAC068905_A	127/128	ACTATGGAATAATGATCTCTGTGCTGAGTTTATTCTTATGGGACTGACAGACC AACCTGAGCTCCAGCTGCCCTTATTGTTCTGTTCTGGTGAACACACAGTCAC TGTGATGGGAAATTTGAGCTTAATGAATCTCAATTCCTAACTCAACCTTCAC ACCCCATGTACTTTTTCATCTTCAACCTGTCTTCACTTCTGTTATTCAAT GGTCTTTACCCCAAAATGCTGATGGCTTTGTTGTAGAGAACAATCATCTCC TTCAGAGGATGCATGACTGACTGCTGTTTCTTCTTATTTTGTGAACCTCTGAGA GTTATGTGCTGACAGCAATGGCCTATGATCGCTATGTGGCCATCTGTGAGCCACT GCTTACAAAGCTGTTATGTCACCTGGCATCTGCTTCTATTGATATTTTGTACTT ATTTGATGGGGCTTGTAGTGCCTTATTCACATACAGGTTTATGATAAGGCTCAA CTTTTGTGATTCTAATGTTATCAACCACTATATGTGTGATATCTTCCCTCTCTTTC GGCTCTCCTGCAGTAGCACCTATCTCACCTGAGCTTGTGAGCTCTGCTGTGGTGG TACAGCTATTATCTTATGTTGCCTCAATATCTTAATCTCTTATGGTATGATCCTTT ACAATATCAATTCATATGTCATCAGTAAGGTTGGTCCAAAGCCTTGGGCACCTTG TGGTCTCACATTATAACTGTTAGCTTGTCTATGTAACTGGGATGCTTGCTTAT GTCAAGCCCATCATCTGCTGAGACTGTGGGACAGGGGAAAATTTTCTCAGTATTTT ACACTTTTGTGTCCTGCTGAATCCTCTTATTACAGCCTCAGAAAACAAGGA TGTCAAAACCTTGCTGTGAAAAAACCTGGAAGAGACTCACATGTTAAATTACCCCA TTCAAAC	MENDSSVSEFILMGLTDQ PELQLPLFVLFVNYTVT VMGNLSLMNLICLNSNLH TPMYFFIFNL SFIDFCYSM VFTPKMLMGFVVEKNIS FRGCMTQLFFFLFFVNSES YVLTAMAYDRYVAICQP LLYKAVMSPGICFLIFCT YLMGLVSALFHTGFMIRL NFCDSNVINHVMCDIFPL FRLSCSSTYLTELVSAAVY GTAILCCLILISYGMILY NIIHMSSGKGWSKALGTC GSHITVSLFYVTGMLAY VKPSSAETVGGQKIFSVF YTFLVPMLNPLYSLRNK DVKLAVKKTWKRLTC

OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.